Differences	O
in	O
expression	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
human	B-cell_line
promyelocytic	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
during	O
differentiation	O
towards	O
macrophages	B-cell_type
versus	O
granulocytes	B-cell_type
.	O

Commitment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
to	O
macrophage	O
or	O
granulocytic	O
differentiation	O
was	O
achieved	O
by	O
incubation	O
with	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
for	O
30-60	O
min	O
or	O
with	O
dimethyl	O
sulphoxide	O
(	O
DMSO	O
)	O
for	O
24	O
h	O
respectively	O
.	O

The	O
commitment	O
stage	O
towards	O
PMA-induced	O
macrophage	O
differentiation	O
was	O
associated	O
with	O
increases	O
in	O
jun	O
B	O
and	O
c-fos	O
mRNA	O
levels	O
,	O
as	O
well	O
as	O
with	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Nevertheless	O
,	O
gel	O
retardation	O
analysis	O
indicated	O
that	O
the	O
AP-1	B-protein
activity	O
detected	O
in	O
untreated	O
cells	O
was	O
drastically	O
reduced	O
during	O
the	O
commitment	O
stage	O
of	O
DMSO-induced	O
HL-60	O
differentiation	O
towards	O
granulocytes	B-cell_type
.	O

When	O
HL-60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
sodium	O
butyrate	O
,	O
which	O
induced	O
monocytic	O
differentiation	O
,	O
a	O
remarkable	O
increase	O
in	O
AP-1	O
binding	O
activity	O
was	O
detected	O
.	O

Treatment	O
of	O
HL-60	B-cell_line
cells	I-cell_line
with	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
,	O
another	O
monocytic	O
differentiation	O
agent	O
,	O
induced	O
a	O
weak	O
,	O
but	O
appreciable	O
,	O
increase	O
in	O
AP-1	B-protein
activity	O
.	O

Furthermore	O
,	O
addition	O
of	O
sodium	O
butyrate	O
or	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
to	O
HL-60	B-cell_line
cells	I-cell_line
induced	O
the	O
expression	O
of	O
c-fos	B-DNA
,	I-DNA
c-jun	I-DNA
,	I-DNA
jun	I-DNA
B	I-DNA
and	I-DNA
jun	I-DNA
D	I-DNA
proto-oncogenes	I-DNA
.	O

In	O
contrast	O
,	O
when	O
HL-60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
retinoic	O
acid	O
,	O
a	O
granulocytic	O
differentiation	O
inducer	O
,	O
no	O
enhanced	O
AP-1	O
binding	O
activity	O
was	O
observed	O
,	O
and	O
only	O
a	O
weak	O
increase	O
in	O
jun	B-RNA
D	I-RNA
mRNA	I-RNA
level	O
was	O
detected	O
.	O

These	O
data	O
indicate	O
that	O
formation	O
of	O
AP-1	B-protein
is	O
not	O
required	O
for	O
the	O
induction	O
of	O
HL-60	B-cell_line
differentiation	O
towards	O
granulocytes	B-cell_type
,	O
whereas	O
induction	O
of	O
monocytic	O
differentiation	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
AP-1	B-protein
activity	O
.	O

The	O
differential	O
expression	O
of	O
AP-1	B-protein
activity	O
may	O
be	O
critical	O
in	O
the	O
differentiation	O
of	O
HL-60	B-cell_line
cells	I-cell_line
towards	O
monocytic	B-cell_type
or	I-cell_type
granulocytic	I-cell_type
lineages	I-cell_type

Biochem	NULL
.	NULL

J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
294	NULL
,	NULL
137-144	NULL
(	NULL
Printed	NULL
in	NULL
Great	NULL
Britain	NULL
)	NULL
137	NULL
Differences	NULL
in	NULL
expression	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
in	NULL
human	NULL
promyelocytic	NULL
HL-60	NULL
cells	NULL
during	NULL
differentiation	NULL
towards	NULL
macrophages	NULL
versus	NULL
granulocytes	NULL
Faustino	NULL
MOLLINEDO	NULL
,	NULL
*§	NULL
Consuelo	NULL
GAJATE	NULL
,	NULL
*	NULL
Antonio	NULL
TUGORES	NULL
,	NULL
f	NULL
Ignacio	NULL
FLORES*	NULL
and	NULL
Jose	NULL
Ramon	NULL
NARANJOF	NULL
*Centro	NULL
de	NULL
Investigaciones	NULL
Biolégicas	NULL
,	NULL
C.S.1.C	NULL
.	NULL

,	NULL
Veldquez	NULL
144	NULL
,	NULL
28006-Madrid	NULL
,	NULL
Servicio	NULL
de	NULL
Inmunologia	NULL
,	NULL
Hospital	NULL
de	NULL
la	NULL
Princesa	NULL
(	NULL
UAM	NULL
)	NULL
,	NULL
Diego	NULL
de	NULL
Leon	NULL
62	NULL
,	NULL
28006-Madrid	NULL
,	NULL
and	NULL
instituto	NULL
Cajal	NULL
de	NULL
Neurociencias	NULL
,	NULL
C.S.1.C	NULL
.	NULL

,	NULL
Doctor	NULL
Arce	NULL
37	NULL
,	NULL
28002-Madrid	NULL
,	NULL
Spain	NULL
Commitment	NULL
of	NULL
HL-60	NULL
cells	NULL
to	NULL
macrophage	NULL
or	NULL
granulocytic	NULL
differentiation	NULL
was	NULL
achieved	NULL
by	NULL
incubation	NULL
with	NULL
4	NULL
$	NULL
-phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
for	NULL
30-60	NULL
min	NULL
or	NULL
with	NULL
dimethyl	NULL
sulphoxide	NULL
(	NULL
DMSO	NULL
)	NULL
for	NULL
24	NULL
h	NULL
respectively	NULL
.	NULL

The	NULL
commitment	NULL
stage	NULL
towards	NULL
PMA-induced	NULL
macrophage	NULL
differentiation	NULL
was	NULL
associated	NULL
with	NULL
increases	NULL
in	NULL
jun	NULL
B	NULL
and	NULL
c-fos	NULL
mRNA	NULL
levels	NULL
,	NULL
as	NULL
well	NULL
as	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
.	NULL

Nevertheless	NULL
,	NULL
gel	NULL
retardation	NULL
analysis	NULL
indicated	NULL
that	NULL
the	NULL
AP-1	NULL
activity	NULL
detected	NULL
in	NULL
untreated	NULL
cells	NULL
was	NULL
drastically	NULL
reduced	NULL
during	NULL
the	NULL
commitment	NULL
stage	NULL
of	NULL
DMSO-induced	NULL
HL-60	NULL
differentiation	NULL
towards	NULL
granulocytes	NULL
.	NULL

When	NULL
HL-60	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
sodium	NULL
butyrate	NULL
,	NULL
which	NULL
induced	NULL
monocytic	NULL
differentiation	NULL
,	NULL
a	NULL
remarkable	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
detected	NULL
.	NULL

Treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
,	NULL
another	NULL
monocytic	NULL
differentiation	NULL
agent	NULL
,	NULL
induced	NULL
a	NULL
weak	NULL
,	NULL
but	NULL
appreciable	NULL
,	NULL
increase	NULL
in	NULL
AP-1	NULL
activity	NULL
.	NULL

Furthermore	NULL
,	NULL
addition	NULL
of	NULL
sodium	NULL
butyrate	NULL
or	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
to	NULL
HL-60	NULL
cells	NULL
induced	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
when	NULL
HL-60	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
retinoic	NULL
acid	NULL
,	NULL
a	NULL
granulocytic	NULL
differentiation	NULL
inducer	NULL
,	NULL
no	NULL
enhanced	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
observed	NULL
,	NULL
and	NULL
only	NULL
a	NULL
weak	NULL
increase	NULL
in	NULL
jun	NULL
D	NULL
mRNA	NULL
level	NULL
was	NULL
detected	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
formation	NULL
of	NULL
AP-1	NULL
is	NULL
not	NULL
required	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
HL-60	NULL
differentiation	NULL
towards	NULL
granulocytes	NULL
,	NULL
whereas	NULL
induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
is	NULL
correlated	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
AP-1	NULL
activity	NULL
.	NULL

The	NULL
differential	NULL
expression	NULL
of	NULL
AP-1	NULL
activity	NULL
may	NULL
be	NULL
critical	NULL
in	NULL
the	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
towards	NULL
monocytic	NULL
or	NULL
granulocytic	NULL
lineages	NULL
.	NULL

INTRODUCTION	NULL
Mature	NULL
blood	NULL
cells	NULL
originate	NULL
from	NULL
a	NULL
self-renewing	NULL
population	NULL
of	NULL
multipotential	NULL
haemopoietic	NULL
stem	NULL
cells	NULL
,	NULL
localized	NULL
mainly	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
,	NULL
which	NULL
generate	NULL
progenitor	NULL
cells	NULL
irreversibly	NULL
committed	NULL
to	NULL
originate	NULL
different	NULL
haemopoietic	NULL
lineages	NULL
.	NULL

Understanding	NULL
of	NULL
the	NULL
molecular	NULL
mechanisms	NULL
that	NULL
control	NULL
differentiation	NULL
and	NULL
maturation	NULL
of	NULL
haemopoietic	NULL
cells	NULL
is	NULL
crucial	NULL
for	NULL
the	NULL
clinical	NULL
manipulation	NULL
of	NULL
blood-cell	NULL
production	NULL
.	NULL

The	NULL
human	NULL
promyelocytic	NULL
HL-60	NULL
cell	NULL
line	NULL
has	NULL
been	NULL
used	NULL
to	NULL
study	NULL
gene	NULL
expression	NULL
during	NULL
the	NULL
differentiation	NULL
of	NULL
myeloid	NULL
cells	NULL
.	NULL

HL-60	NULL
cells	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
differentiate	NULL
into	NULL
granulocyte-like	NULL
cells	NULL
by	NULL
treatment	NULL
with	NULL
dimethyt	NULL
sulphoxide	NULL
(	NULL
DMSO	NULL
)	NULL
or	NULL
retinoic	NULL
acid	NULL
[	NULL
1-4	NULL
]	NULL
,	NULL
whereas	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
4	NULL
#	NULL
-phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
sodium	NULL
butyrate	NULL
or	NULL
1	NULL
«	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
results	NULL
in	NULL
differentiation	NULL
towards	NULL
the	NULL
monocytic	NULL
lineage	NULL
[	NULL
2,5-7	NULL
]	NULL
.	NULL

PMA	NULL
induces	NULL
HL-60	NULL
to	NULL
differentiate	NULL
to	NULL
cells	NULL
exhibiting	NULL
macrophage	NULL
characteristics	NULL
,	NULL
while	NULL
sodium	NULL
butyrate	NULL
and	NULL
vitamin	NULL
D	NULL
,	NULL
induce	NULL
HL-60	NULL
cells	NULL
to	NULL
differentiate	NULL
towards	NULL
cells	NULL
showing	NULL
monocyte	NULL
characteristics	NULL
[	NULL
2,5-7	NULL
]	NULL
.	NULL

Expression	NULL
of	NULL
nuclear	NULL
proto-oncogenes	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
cellular	NULL
proliferation	NULL
and	NULL
differentiation	NULL
[	NULL
8,9	NULL
]	NULL
.	NULL

Previous	NULL
studies	NULL
in	NULL
embryonal	NULL
carcinoma	NULL
cells	NULL
have	NULL
suggested	NULL
a	NULL
role	NULL
for	NULL
c-jun	NULL
in	NULL
cell	NULL
differentiation	NULL
[	NULL
10	NULL
]	NULL
.	NULL

The	NULL
nuclear	NULL
proto-oncogene	NULL
c-jun	NULL
encodes	NULL
for	NULL
a	NULL
component	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
[	NULL
11,12	NULL
]	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
regulatory	NULL
sequences	NULL
upstream	NULL
of	NULL
numerous	NULL
viral	NULL
and	NULL
cellular	NULL
promoters	NULL
and	NULL
is	NULL
important	NULL
in	NULL
regulating	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
these	NULL
genes	NULL
[	NULL
11-14	NULL
]	NULL
.	NULL

c-Jun/AP-1	NULL
homodimer	NULL
binds	NULL
weakly	NULL
to	NULL
the	NULL
heptameric	NULL
DNA	NULL
consensus	NULL
sequence	NULL
TGA	NULL
(	NULL
C/G	NULL
)	NULL
TCA	NULL
,	NULL
but	NULL
the	NULL
binding	NULL
affinity	NULL
of	NULL
AP-1	NULL
for	NULL
its	NULL
cognate	NULL
sequence	NULL
dramatically	NULL
increases	NULL
when	NULL
heterodimerization	NULL
with	NULL
c-Fos	NULL
occurs	NULL
[	NULL
13-19	NULL
]	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
c-Fos/c-Jun	NULL
heterodimer	NULL
has	NULL
a	NULL
much	NULL
higher	NULL
affinity	NULL
to	NULL
the	NULL
AP-1	NULL
enhancer	NULL
sequence	NULL
than	NULL
the	NULL
c-Jun	NULL
homodimer	NULL
,	NULL
whereas	NULL
c-Fos	NULL
is	NULL
not	NULL
able	NULL
to	NULL
form	NULL
homodimers	NULL
[	NULL
13-19	NULL
]	NULL
.	NULL

As	NULL
dimer	NULL
formation	NULL
,	NULL
mediated	NULL
through	NULL
the	NULL
'leucine	NULL
zipper	NULL
'	NULL
domains	NULL
,	NULL
is	NULL
a	NULL
prerequisite	NULL
for	NULL
high-affinity	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
c-Fos	NULL
does	NULL
not	NULL
bind	NULL
DNA	NULL
by	NULL
its	NULL
own	NULL
[	NULL
13-19	NULL
]	NULL
and	NULL
therefore	NULL
does	NULL
not	NULL
stimulate	NULL
transcription	NULL
in	NULL
c-Jun	NULL
's	NULL
absence	NULL
[	NULL
20,21	NULL
]	NULL
.	NULL

Two	NULL
related	NULL
proteins	NULL
,	NULL
named	NULL
Jun	NULL
B	NULL
and	NULL
Jun	NULL
D	NULL
,	NULL
have	NULL
similar	NULL
structures	NULL
to	NULL
c-Jun	NULL
and	NULL
also	NULL
form	NULL
nuclear	NULL
complexes	NULL
with	NULL
c-Fos	NULL
or	NULL
Fos-related	NULL
proteins	NULL
[	NULL
22-24	NULL
]	NULL
.	NULL

However	NULL
,	NULL
in	NULL
spite	NULL
of	NULL
these	NULL
structural	NULL
similarities	NULL
,	NULL
the	NULL
three	NULL
members	NULL
of	NULL
the	NULL
jun	NULL
family	NULL
are	NULL
differently	NULL
expressed	NULL
during	NULL
development	NULL
[	NULL
25	NULL
]	NULL
as	NULL
well	NULL
as	NULL
in	NULL
distinct	NULL
tissues	NULL
[	NULL
24,26,27	NULL
]	NULL
and	NULL
cell	NULL
lines	NULL
[	NULL
26,28	NULL
]	NULL
.	NULL

Furthermore	NULL
,	NULL
Jun	NULL
proteins	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
different	NULL
biochemical	NULL
and	NULL
physiological	NULL
properties	NULL
,	NULL
displaying	NULL
distinct	NULL
DNA	NULL
binding	NULL
and	NULL
transactivating	NULL
activities	NULL
[	NULL
20,29	NULL
]	NULL
.	NULL

Thus	NULL
Jun	NULL
B	NULL
is	NULL
an	NULL
efficient	NULL
activator	NULL
of	NULL
artificial	NULL
promoters	NULL
which	NULL
contain	NULL
multimeric	NULL
AP-1	NULL
sites	NULL
,	NULL
but	NULL
inhibits	NULL
transactivation	NULL
by	NULL
c-Jun	NULL
on	NULL
promoters	NULL
containing	NULL
only	NULL
one	NULL
AP-1	NULL
site	NULL
[	NULL
30	NULL
]	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
Jun	NULL
proteins	NULL
play	NULL
distinct	NULL
roles	NULL
in	NULL
regulating	NULL
gene	NULL
expression	NULL
and	NULL
might	NULL
be	NULL
used	NULL
differently	NULL
by	NULL
various	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
external	NULL
or	NULL
internal	NULL
environmental	NULL
stimuli	NULL
.	NULL

Induction	NULL
of	NULL
c-fos	NULL
mature	NULL
transcripts	NULL
has	NULL
been	NULL
detected	NULL
during	NULL
monocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
induced	NULL
by	NULL
PMA	NULL
or	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
[	NULL
31,32	NULL
]	NULL
.	NULL

However	NULL
,	NULL
other	NULL
studies	NULL
suggest	NULL
that	NULL
c-fos	NULL
expression	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
commit	NULL
cells	NULL
towards	NULL
monocytic	NULL
differentiation	NULL
[	NULL
33,34	NULL
]	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
Abbreviations	NULL
used	NULL
:	NULL
DMSO	NULL
,	NULL
dimethyl	NULL
sulphoxide	NULL
;	NULL
PMA	NULL
,	NULL
4	NULL
$	NULL
-phorbot	NULL
12-myristate	NULL
13-acetate	NULL
.	NULL

§	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

138	NULL
F.	NULL
Mollinedo	NULL
and	NULL
others	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
towards	NULL
granulocytic	NULL
lineage	NULL
by	NULL
DMSO	NULL
does	NULL
not	NULL
induce	NULL
appreciable	NULL
levels	NULL
of	NULL
c-fos	NULL
transcripts	NULL
[	NULL
31	NULL
]	NULL
.	NULL

Induction	NULL
of	NULL
c-jur	NULL
mature	NULL
transcripts	NULL
has	NULL
been	NULL
recently	NULL
reported	NULL
during	NULL
monocytic	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
{	NULL
28,35,36	NULL
]	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
c-jun	NULL
mRNA	NULL
expression	NULL
is	NULL
not	NULL
detected	NULL
when	NULL
HL-60	NULL
cells	NULL
are	NULL
induced	NULL
to	NULL
differentiate	NULL
towards	NULL
granulocyte-like	NULL
cells	NULL
by	NULL
treatment	NULL
with	NULL
DMSO	NULL
[	NULL
28,36	NULL
]	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
reported	NULL
a	NULL
distinct	NULL
expression	NULL
of	NULL
c-jun	NULL
,	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
during	NULL
PMA-induced	NULL
HL-60	NULL
differentiation	NULL
[	NULL
28	NULL
]	NULL
,	NULL
and	NULL
an	NULL
increase	NULL
in	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
mRNA	NULL
levels	NULL
during	NULL
DMSO-induced	NULL
HL-60	NULL
differentiation	NULL
[	NULL
28	NULL
]	NULL
.	NULL

However	NULL
,	NULL
the	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
not	NULL
examined	NULL
in	NULL
those	NULL
studies	NULL
.	NULL

As	NULL
expression	NULL
of	NULL
distinct	NULL
jun	NULL
proto-oncogenes	NULL
can	NULL
be	NULL
induced	NULL
during	NULL
monocytic	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
[	NULL
28,36	NULL
]	NULL
,	NULL
we	NULL
have	NULL
analysed	NULL
in	NULL
the	NULL
present	NULL
study	NULL
whether	NULL
the	NULL
expression	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
activity	NULL
was	NULL
correlated	NULL
with	NULL
the	NULL
time	NULL
required	NULL
to	NULL
commit	NULL
HL-60	NULL
cells	NULL
to	NULL
differentiate	NULL
towards	NULL
macrophages	NULL
and	NULL
granulocytes	NULL
.	NULL

By	NULL
examining	NULL
the	NULL
expression	NULL
of	NULL
AP-1	NULL
binding	NULL
activity	NULL
,	NULL
we	NULL
report	NULL
here	NULL
that	NULL
the	NULL
basal	NULL
AP-1	NULL
activity	NULL
observed	NULL
in	NULL
untreated	NULL
HL-60	NULL
cells	NULL
is	NULL
increased	NULL
during	NULL
monocyte/	NULL
macrophage	NULL
differentiation	NULL
and	NULL
decreased	NULL
,	NULL
or	NULL
not	NULL
affected	NULL
,	NULL
during	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

Furthermore	NULL
,	NULL
induction	NULL
of	NULL
HL-60	NULL
differentiation	NULL
towards	NULL
the	NULL
monocytic	NULL
or	NULL
granulocytic	NULL
lineages	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
distinct	NULL
expression	NULL
of	NULL
fos	NULL
and	NULL
jun	NULL
proto-oncogenes	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
mRNA	NULL
being	NULL
rapidly	NULL
increased	NULL
during	NULL
induction	NULL
of	NULL
monocyte/macrophage	NULL
differentiation	NULL
.	NULL

The	NULL
present	NULL
studies	NULL
suggest	NULL
that	NULL
qualitative	NULL
and	NULL
quantitative	NULL
differences	NULL
in	NULL
AP-1	NULL
expression	NULL
occur	NULL
during	NULL
monocytic	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Materials	NULL
RPMI	NULL
1640	NULL
culture	NULL
medium	NULL
,	NULL
fetal-calf	NULL
serum	NULL
and	NULL
L-glutamine	NULL
were	NULL
purchased	NULL
from	NULL
Flow	NULL
Laboratories	NULL
(	NULL
Irvine	NULL
,	NULL
Ayrshire	NULL
,	NULL
Scotland	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

Antibiotics	NULL
were	NULL
from	NULL
Laboratorios	NULL
Llorente	NULL
(	NULL
Madrid	NULL
,	NULL
Spain	NULL
)	NULL
.	NULL

BSA	NULL
,	NULL
retinoic	NULL
acid	NULL
(	NULL
all-trans	NULL
)	NULL
,	NULL
sodium	NULL
butyrate	NULL
and	NULL
PMA	NULL
were	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

PMA	NULL
was	NULL
dissolved	NULL
in	NULL
DMSO	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
2	NULL
mg/ml	NULL
and	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
20	NULL
ng/ml	NULL
.	NULL

Controls	NULL
containing	NULL
equivalent	NULL
amounts	NULL
(	NULL
0.05	NULL
%	NULL
,	NULL
v/v	NULL
)	NULL
of	NULL
DMSO	NULL
were	NULL
run	NULL
in	NULL
parallel	NULL
,	NULL
and	NULL
no	NULL
effect	NULL
on	NULL
either	NULL
cell	NULL
differentiation	NULL
or	NULL
gene	NULL
expression	NULL
was	NULL
observed	NULL
.	NULL

Retinoic	NULL
acid	NULL
was	NULL
prepared	NULL
as	NULL
a	NULL
1	NULL
mM	NULL
stock	NULL
in	NULL
ethanol	NULL
and	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
«	NULL
M	NULL
in	NULL
culture	NULL
.	NULL

1	NULL
@	NULL
,25-Dihydroxyvitamin	NULL
D	NULL
,	NULL
,	NULL
generously	NULL
given	NULL
by	NULL
Dr.	NULL
M.	NULL
Uskokovie	NULL
(	NULL
Hoffmann-La	NULL
Roche	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
,	NULL
U.S.A.	NULL
)	NULL
,	NULL
was	NULL
prepared	NULL
as	NULL
a	NULL
10°	NULL
M	NULL
stock	NULL
in	NULL
ethanol	NULL
and	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10-®	NULL
M	NULL
in	NULL
culture	NULL
.	NULL

Sodium	NULL
butyrate	NULL
was	NULL
prepared	NULL
as	NULL
a	NULL
1	NULL
M	NULL
stock	NULL
solution	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
3	NULL
mM	NULL
in	NULL
culture	NULL
.	NULL

The	NULL
retinoic	NULL
acid	NULL
,	NULL
PMA	NULL
and	NULL
1	NULL
@	NULL
,25-dihydoxyvitamin	NULL
D	NULL
,	NULL
stock	NULL
solutions	NULL
were	NULL
stored	NULL
at	NULL
-20	NULL
°C	NULL
.	NULL

Sodium	NULL
butyrate	NULL
was	NULL
freshly	NULL
prepared	NULL
and	NULL
stored	NULL
refrigerated	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

In	NULL
control	NULL
experiments	NULL
carrier	NULL
blanks	NULL
failed	NULL
to	NULL
affect	NULL
gene	NULL
expression	NULL
or	NULL
induce	NULL
differentiation	NULL
.	NULL

Fluorescein	NULL
isothiocyanate-conjugated	NULL
rabbit	NULL
anti-mouse	NULL
IgG	NULL
was	NULL
purchased	NULL
from	NULL
Dakopatts	NULL
(	NULL
Glostrup	NULL
,	NULL
Denmark	NULL
)	NULL
.	NULL

Acrylamide	NULL
,	NULL
bisacryl-amide	NULL
,	NULL
ammonium	NULL
persulphate	NULL
and	NULL
NNN	NULL
'	NULL
N'-tetramethyl-ethylenediamine	NULL
were	NULL
from	NULL
Bio-Rad	NULL
(	NULL
Richmond	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Guanidine	NULL
thiocyanate	NULL
and	NULL
formamide	NULL
were	NULL
from	NULL
Fluka	NULL
(	NULL
Buchs	NULL
,	NULL
Switzerland	NULL
)	NULL
.	NULL

Formaldehyde	NULL
was	NULL
from	NULL
J.	NULL
T.	NULL
Baker	NULL
Chemicals	NULL
B.	NULL
V.	NULL
(	NULL
Deventer	NULL
,	NULL
Holland	NULL
)	NULL
.	NULL

All	NULL
other	NULL
chemicals	NULL
were	NULL
from	NULL
Sigma	NULL
and	NULL
Merck	NULL
(	NULL
Darmstadt	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

The	NULL
anti-Mol	NULL
alpha	NULL
subunit	NULL
(	NULL
CD1l1lb	NULL
)	NULL
Bear-l	NULL
monoclonal	NULL
antibody	NULL
was	NULL
generously	NULL
given	NULL
by	NULL
Dr.	NULL
J.	NULL
E.	NULL
De	NULL
Vries	NULL
(	NULL
Unicet	NULL
,	NULL
Lyon	NULL
,	NULL
France	NULL
)	NULL
[	NULL
37	NULL
]	NULL
.	NULL

P3X63	NULL
myeloma	NULL
culture	NULL
supernatant	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

The	NULL
anti-Fos	NULL
antibody	NULL
,	NULL
against	NULL
the	NULL
M	NULL
peptide	NULL
[	NULL
38	NULL
]	NULL
was	NULL
generously	NULL
given	NULL
by	NULL
Dr.	NULL
M.	NULL
J.	NULL
Iadarola	NULL
(	NULL
NIDR	NULL
,	NULL
NIH	NULL
,	NULL
Bethesda	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Cells	NULL
The	NULL
human	NULL
cell	NULL
line	NULL
HL-60	NULL
was	NULL
grown	NULL
at	NULL
37	NULL
°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
(	NULL
CO	NULL
,	NULL
/air	NULL
,	NULL
1:19	NULL
)	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
heat-inactivated	NULL
fetal-calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
and	NULL
24	NULL
ug/ml	NULL
gentamicin	NULL
.	NULL

Cell	NULL
differentiation	NULL
was	NULL
induced	NULL
by	NULL
adding	NULL
20	NULL
ng/ml	NULL
PMA	NULL
,	NULL
3	NULL
mM	NULL
sodium	NULL
butyrate	NULL
,	NULL
10~®	NULL
M	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
,	NULL
1	NULL
gM	NULL
retinoic	NULL
acid	NULL
or	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
in	NULL
the	NULL
respective	NULL
Figure	NULL
legends	NULL
.	NULL

Cell	NULL
differentiation	NULL
was	NULL
monitored	NULL
by	NULL
CD11b	NULL
antigen	NULL
expression	NULL
,	NULL
cell-cluster	NULL
formation	NULL
,	NULL
adhesion	NULL
to	NULL
culture	NULL
plates	NULL
,	NULL
non-specific	NULL
esterase	NULL
activity	NULL
and	NULL
cell	NULL
morphology	NULL
[	NULL
2	NULL
]	NULL
.	NULL

Adherent	NULL
macrophage-differentiated	NULL
HL-60	NULL
cells	NULL
were	NULL
scraped	NULL
off	NULL
with	NULL
a	NULL
rubber	NULL
policeman	NULL
and	NULL
washed	NULL
with	NULL
sterile	NULL
phosphate-buffered	NULL
saline	NULL
before	NULL
the	NULL
isolation	NULL
of	NULL
either	NULL
total	NULL
RNA	NULL
or	NULL
nuclei	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
evaluated	NULL
by	NULL
Trypan	NULL
Blue	NULL
exclusion	NULL
and	NULL
was	NULL
always	NULL
higher	NULL
than	NULL
98	NULL
%	NULL
.	NULL

Immunofluorescence	NULL
flow	NULL
cytometry	NULL
Fluorescence-flow-cytometry	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
an	NULL
EPICS-C	NULL
cytofluorimeter	NULL
(	NULL
Coulter	NULL
Cientifica	NULL
,	NULL
Mostoles	NULL
,	NULL
Spain	NULL
)	NULL
as	NULL
described	NULL
in	NULL
[	NULL
39	NULL
]	NULL
.	NULL

Fluorescence	NULL
data	NULL
were	NULL
collected	NULL
on	NULL
a	NULL
logarithmic	NULL
scale	NULL
.	NULL

Negative	NULL
controls	NULL
were	NULL
obtained	NULL
using	NULL
P3X63	NULL
myeloma	NULL
supernatant	NULL
instead	NULL
of	NULL
the	NULL
anti-CD1l1b	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Northern-blot	NULL
analysis	NULL
Total	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
the	NULL
guanidine	NULL
thiocyanate/CsCl	NULL
method	NULL
[	NULL
40	NULL
]	NULL
.	NULL

Samples	NULL
of	NULL
20	NULL
ug	NULL
of	NULL
RNA	NULL
were	NULL
electrophoresed	NULL
on	NULL
1.1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
agarose-formaldehyde	NULL
gels	NULL
,	NULL
followed	NULL
by	NULL
transfer	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
(	NULL
Schleicher	NULL
und	NULL
Schuell	NULL
,	NULL
Dassel	NULL
,	NULL
Germany	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
[	NULL
41	NULL
]	NULL
.	NULL

**P-labelled	NULL
cDNA	NULL
probes	NULL
were	NULL
prepared	NULL
using	NULL
the	NULL
random	NULL
hexanucleotide	NULL
priming	NULL
method	NULL
[	NULL
42	NULL
]	NULL
(	NULL
Oligo-Labelling	NULL
Kit	NULL
;	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
to	NULL
a	NULL
specific	NULL
radioactivity	NULL
equal	NULL
to	NULL
,	NULL
or	NULL
higher	NULL
than	NULL
,	NULL
7	NULL
x	NULL
10°	NULL
c.p.m./ug	NULL
of	NULL
cDNA	NULL
.	NULL

cDNA	NULL
probes	NULL
for	NULL
c-fos	NULL
[	NULL
43	NULL
]	NULL
,	NULL
c-jun	NULL
[	NULL
44	NULL
]	NULL
,	NULL
jun	NULL
B	NULL
[	NULL
26	NULL
]	NULL
and	NULL
jun	NULL
D	NULL
[	NULL
24	NULL
]	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
P.	NULL
Sassone-Corsi	NULL
(	NULL
LGME	NULL
,	NULL
CNRS	NULL
,	NULL
Strasbourg	NULL
,	NULL
France	NULL
)	NULL
and	NULL
Dr.	NULL
R.	NULL
Bravo	NULL
(	NULL
Squibb	NULL
Institute	NULL
,	NULL
Princeton	NULL
,	NULL
NJ	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

Under	NULL
the	NULL
experimental	NULL
conditions	NULL
used	NULL
in	NULL
the	NULL
Northern-blot	NULL
analysis	NULL
,	NULL
there	NULL
was	NULL
no	NULL
cross-reactivity	NULL
among	NULL
the	NULL
above	NULL
probes	NULL
[	NULL
28,45	NULL
]	NULL
.	NULL

Northern	NULL
blots	NULL
were	NULL
prehybrid-ized	NULL
at	NULL
42	NULL
°C	NULL
for	NULL
6-24	NULL
h	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
40	NULL
%	NULL
formamide	NULL
,	NULL
4x	NULL
SSC	NULL
(	NULL
1xSSC	NULL
is	NULL
0.15	NULL
M	NULL
NaCI1/0.015	NULL
M	NULL
sodium	NULL
citrate	NULL
)	NULL
,	NULL
4	NULL
x	NULL
Denhardt	NULL
's	NULL
solution	NULL
(	NULL
1	NULL
x	NULL
Denhardt	NULL
's	NULL
solution	NULL
is	NULL
0.02	NULL
%	NULL
BSA/	NULL
0.02	NULL
%	NULL
Ficoll-400/0.02	NULL
%	NULL
polyvinylpyrrolidone	NULL
)	NULL
and	NULL
salmon	NULL
sperm	NULL
DNA	NULL
(	NULL
80	NULL
4g/ml	NULL
)	NULL
.	NULL

Then	NULL
blots	NULL
were	NULL
hybridized	NULL
in	NULL
the	NULL
above	NULL
buffer	NULL
containing	NULL
1	NULL
x	NULL
Denhardt	NULL
's	NULL
solution	NULL
,	NULL
10	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
dextran	NULL
sulphate	NULL
and	NULL
about	NULL
5	NULL
x	NULL
10°	NULL
c.p.m	NULL
.	NULL

of	NULL
probe	NULL
at	NULL
42	NULL
°C	NULL
for	NULL
16-24	NULL
h.	NULL
After	NULL
hybridization	NULL
,	NULL
blots	NULL
were	NULL
washed	NULL
once	NULL
in	NULL
2x	NULL
SSC/0.1	NULL
%	NULL
SDS	NULL
for	NULL
30	NULL
min	NULL
at	NULL
42	NULL
°C	NULL
,	NULL
once	NULL
in	NULL
0.1	NULL
x	NULL
SSC/0.1	NULL
%	NULL
SDS	NULL
for	NULL
1	NULL
h	NULL
at	NULL
55	NULL
°C	NULL
,	NULL
and	NULL
once	NULL
more	NULL
with	NULL
the	NULL
same	NULL
buffer	NULL
for	NULL
15	NULL
min	NULL
at	NULL
55	NULL
°C	NULL
.	NULL

Subsequently	NULL
,	NULL
blots	NULL
were	NULL
air-dried	NULL
and	NULL
exposed	NULL
to	NULL
Kodak	NULL
X-Omat	NULL
film	NULL
with	NULL
enhancing	NULL
screens	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

*P-labelled	NULL
probes	NULL
were	NULL
removed	NULL
from	NULL
nitrocellulose	NULL
membranes	NULL
by	NULL
immersion	NULL
in	NULL
boiling	NULL
2	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
for	NULL
2-3	NULL
min	NULL
.	NULL

Before	NULL
hybridization	NULL
to	NULL
a	NULL
second	NULL
probe	NULL
,	NULL
removal	NULL
of	NULL
radioactivity	NULL
was	NULL
verified	NULL
by	NULL
autoradiography	NULL
.	NULL

AP-1	NULL
activity	NULL
during	NULL
myeloid	NULL
differentiation	NULL
139	NULL
Nuclear	NULL
extracts	NULL
and	NULL
gel	NULL
retardation	NULL
assays	NULL
Mini-nuclear	NULL
extracts	NULL
were	NULL
obtained	NULL
from	NULL
about	NULL
3	NULL
x	NULL
10°	NULL
cells	NULL
,	NULL
essentially	NULL
as	NULL
described	NULL
in	NULL
[	NULL
46	NULL
]	NULL
,	NULL
with	NULL
some	NULL
modifications	NULL
.	NULL

Briefly	NULL
,	NULL
buffer	NULL
A	NULL
was	NULL
supplemented	NULL
with	NULL
0.75	NULL
mM	NULL
spermidine	NULL
,	NULL
0.15	NULL
mM	NULL
spermine	NULL
,	NULL
2	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
2	NULL
ug/ml	NULL
leupeptin	NULL
and	NULL
10	NULL
mM	NULL
Na	NULL
,	NULL
MOoO	NULL
,	NULL
.	NULL

Buffer	NULL
C	NULL
was	NULL
also	NULL
supplemented	NULL
with	NULL
2	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
2	NULL
ug/ml	NULL
leupeptin	NULL
and	NULL
10	NULL
mM	NULL
Na	NULL
,	NULL
MoO	NULL
,	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
determined	NULL
in	NULL
5	NULL
wl	NULL
of	NULL
each	NULL
sample	NULL
by	NULL
the	NULL
Bradford	NULL
method	NULL
[	NULL
47	NULL
]	NULL
,	NULL
using	NULL
a	NULL
Bio-Rad	NULL
kit	NULL
and	NULL
BSA	NULL
as	NULL
standard	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
was	NULL
about	NULL
1	NULL
ug/ul	NULL
for	NULL
nuclear	NULL
extracts	NULL
(	NULL
final	NULL
volume	NULL
,	NULL
50	NULL
wl	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
l	NULL
containing	NULL
0.5	NULL
x	NULL
buffer	NULL
C	NULL
,	NULL
4	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
,	NULL
6	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.45	NULL
pmol	NULL
of	NULL
**P-labelled	NULL
double-stranded	NULL
oligonucleotide	NULL
and	NULL
44g	NULL
of	NULL
nuclear	NULL
protein	NULL
.	NULL

After	NULL
15	NULL
min	NULL
of	NULL
incubation	NULL
on	NULL
ice	NULL
,	NULL
1.5	NULL
wl	NULL
of	NULL
loading	NULL
buffer	NULL
[	NULL
10	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
/10	NULL
%	NULL
glycerol/0.01	NULL
%	NULL
Bromophenol	NULL
Blue	NULL
]	NULL
were	NULL
added	NULL
,	NULL
and	NULL
14	NULL
ul	NULL
of	NULL
each	NULL
reaction	NULL
mixture	NULL
were	NULL
run	NULL
through	NULL
4.5	NULL
%	NULL
acrylamide/bisacrylamide	NULL
(	NULL
29:1	NULL
)	NULL
/0.4	NULL
x	NULL
TBE	NULL
(	NULL
1	NULL
x	NULL
TBE	NULL
is	NULL
0.089	NULL
M	NULL
Tris	NULL
base/0.089	NULL
M	NULL
boric	NULL
acid/2	NULL
mM	NULL
EDTA	NULL
)	NULL
non-denaturing	NULL
gels	NULL
as	NULL
described	NULL
in	NULL
[	NULL
48	NULL
]	NULL
.	NULL

Polyacrylamide	NULL
gels	NULL
were	NULL
run	NULL
at	NULL
200	NULL
V	NULL
in	NULL
0.4	NULL
x	NULL
TBE	NULL
,	NULL
dried	NULL
under	NULL
vacuum	NULL
at	NULL
80	NULL
°C	NULL
and	NULL
subjected	NULL
to	NULL
autoradiography	NULL
with	NULL
enhancing	NULL
screens	NULL
overnight	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

The	NULL
double-stranded	NULL
oligonucleotide	NULL
used	NULL
in	NULL
the	NULL
gel-retardation	NULL
assays	NULL
was	NULL
a	NULL
synthetic	NULL
22	NULL
bp	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
AP-1	NULL
consensus	NULL
sequence	NULL
(	NULL
5-CTAGTGATGAGTCAGCCGGATC-3	NULL
'	NULL
)	NULL
[	NULL
49	NULL
]	NULL
.	NULL

Oligonucleotides	NULL
were	NULL
synthesized	NULL
in	NULL
a	NULL
Cyclone	NULL
Plus	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Milligen	NULL
,	NULL
Novato	NULL
,	NULL
CA	NULL
,	NULL
U.S.A.	NULL
)	NULL
and	NULL
purified	NULL
by	NULL
electrophoresis	NULL
through	NULL
denaturing	NULL
acrylamide	NULL
gels	NULL
.	NULL

After	NULL
elution	NULL
,	NULL
complementary	NULL
oligonucleotides	NULL
were	NULL
annealed	NULL
,	NULL
and	NULL
double-stranded	NULL
products	NULL
were	NULL
end-labelled	NULL
by	NULL
fill-in	NULL
reaction	NULL
using	NULL
reverse	NULL
transcriptase	NULL
.	NULL

In	NULL
order	NULL
to	NULL
block	NULL
binding	NULL
of	NULL
AP-1	NULL
to	NULL
the	NULL
consensus	NULL
sequence	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
4	NULL
ug	NULL
of	NULL
protein	NULL
)	NULL
were	NULL
preincubated	NULL
with	NULL
1	NULL
wl	NULL
of	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
peptide	NULL
)	NULL
antiserum	NULL
for	NULL
12h	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
then	NULL
samples	NULL
were	NULL
subjected	NULL
to	NULL
the	NULL
gel-retardation	NULL
assay	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Controls	NULL
preincubated	NULL
with	NULL
1	NULL
wl	NULL
of	NULL
preimmune	NULL
rabbit	NULL
serum	NULL
for	NULL
12	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
were	NULL
run	NULL
in	NULL
parallel	NULL
.	NULL

RESULTS	NULL
Induction	NULL
of	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
expression	NULL
during	NULL
commitment	NULL
of	NULL
PMA-	NULL
and	NULL
DMSO-induced	NULL
HL-GO	NULL
cell	NULL
differentiation	NULL
Complete	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
towards	NULL
macrophage-	NULL
or	NULL
granulocyte-like	NULL
cells	NULL
was	NULL
rendered	NULL
after	NULL
treatment	NULL
with	NULL
20	NULL
ng/ml	NULL
PMA	NULL
for	NULL
24	NULL
h	NULL
or	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
7	NULL
days	NULL
respectively	NULL
.	NULL

It	NULL
had	NULL
been	NULL
previously	NULL
reported	NULL
that	NULL
commitment	NULL
of	NULL
the	NULL
myeloid	NULL
human	NULL
cell	NULL
line	NULL
HL-60	NULL
to	NULL
the	NULL
macrophage	NULL
differentiation	NULL
pathway	NULL
occurred	NULL
during	NULL
the	NULL
first	NULL
30-60	NULL
min	NULL
of	NULL
phorbol	NULL
ester	NULL
treatment	NULL
[	NULL
31	NULL
]	NULL
.	NULL

We	NULL
found	NULL
that	NULL
addition	NULL
of	NULL
DMSO	NULL
for	NULL
24	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
its	NULL
removal	NULL
from	NULL
the	NULL
medium	NULL
,	NULL
was	NULL
sufficient	NULL
to	NULL
commit	NULL
the	NULL
HL-60	NULL
cell	NULL
line	NULL
to	NULL
a	NULL
granulocytic	NULL
differentiation	NULL
pathway	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
,	NULL
as	NULL
assessed	NULL
by	NULL
expression	NULL
of	NULL
the	NULL
differentiation	NULL
antigen	NULL
CDI11b	NULL
,	NULL
which	NULL
is	NULL
a	NULL
marker	NULL
of	NULL
myeloid	NULL
differentiation	NULL
.	NULL

Figure	NULL
1	NULL
shows	NULL
the	NULL
percentages	NULL
of	NULL
positive	NULL
cells	NULL
for	NULL
CD11b	NULL
antigen	NULL
in	NULL
untreated	NULL
control	NULL
HL-60	NULL
cells	NULL
(	NULL
Figure	NULL
1a	NULL
,	NULL
left	NULL
)	NULL
and	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
DMSO	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
(	NULL
Figure	NULL
1b	NULL
,	NULL
left	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
in	NULL
HL-60	NULL
cells	NULL
treated	NULL
for	NULL
72	NULL
h	NULL
with	NULL
DMSO	NULL
(	NULL
Figure	NULL
la	NULL
,	NULL
right	NULL
)	NULL
.	NULL

Other	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
DMSO	NULL
for	NULL
6	NULL
,	NULL
24	NULL
or	NULL
48	NULL
h	NULL
,	NULL
and	NULL
then	NULL
thoroughly	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
DMSO	NULL
up	NULL
to	NULL
72	NULL
h	NULL
(	NULL
Figure	NULL
1b	NULL
,	NULL
right	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
24	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
successive	NULL
washing	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
then	NULL
cultured	NULL
in	NULL
DMSO-free	NULL
culture	NULL
medium	NULL
for	NULL
additional	NULL
48	NULL
h	NULL
,	NULL
showed	NULL
a	NULL
percentage	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
similar	NULL
to	NULL
that	NULL
obtained	NULL
with	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
72	NULL
h	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
preincubation	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
24	NULL
h	NULL
is	NULL
sufficient	NULL
to	NULL
commit	NULL
cells	NULL
towards	NULL
granulocytic	NULL
differentiation	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

We	NULL
found	NULL
accumulation	NULL
of	NULL
c-fos	NULL
specific	NULL
2.2	NULL
kb	NULL
transcripts	NULL
and	NULL
jun	NULL
B	NULL
specific	NULL
2.1	NULL
kb	NULL
transcripts	NULL
after	NULL
30	NULL
min	NULL
of	NULL
PMA	NULL
addition	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
,	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
results	NULL
of	NULL
previous	NULL
studies	NULL
[	NULL
28,31	NULL
]	NULL
.	NULL

The	NULL
sizes	NULL
of	NULL
2.2	NULL
kb	NULL
and	NULL
2.1	NULL
kb	NULL
for	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
transcripts	NULL
respectively	NULL
,	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
already	NULL
reported	NULL
[	NULL
26,43,45,50	NULL
]	NULL
.	NULL

In	NULL
a	NULL
previous	NULL
study	NULL
[	NULL
28	NULL
]	NULL
we	NULL
found	NULL
by	NULL
Northern-blot	NULL
analysis	NULL
a	NULL
small	NULL
,	NULL
transient	NULL
and	NULL
rapid	NULL
increase	NULL
of	NULL
c-jun	NULL
mRNA	NULL
levels	NULL
after	NULL
15-30	NULL
min	NULL
after	NULL
PMA	NULL
addition	NULL
,	NULL
returning	NULL
to	NULL
basal	NULL
levels	NULL
after	NULL
1	NULL
h	NULL
of	NULL
treatment	NULL
.	NULL

However	NULL
,	NULL
maximal	NULL
induction	NULL
of	NULL
c-jun	NULL
mRNA	NULL
level	NULL
was	NULL
achieved	NULL
24	NULL
h	NULL
after	NULL
PMA	NULL
addition	NULL
[	NULL
28	NULL
]	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
the	NULL
c-jun	NULL
and	NULL
c-fos	NULL
mRNA	NULL
levels	NULL
has	NULL
been	NULL
detected	NULL
during	NULL
granulocytic	NULL
HL-60	NULL
differentiation	NULL
induced	NULL
by	NULL
DMSO	NULL
[	NULL
28,31,36	NULL
]	NULL
.	NULL

Corroborating	NULL
these	NULL
reports	NULL
,	NULL
we	NULL
found	NULL
that	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
10	NULL
min	NULL
,	NULL
30	NULL
min	NULL
,	NULL
1	NULL
h	NULL
,	NULL
6	NULL
h	NULL
and	NULL
24	NULL
h	NULL
did	NULL
not	NULL
induce	NULL
accumulation	NULL
of	NULL
c-fos	NULL
transcripts	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
we	NULL
have	NULL
(	NULL
a	NULL
)	NULL
Control	NULL
61	NULL
Relative	NULL
no	NULL
.	NULL

of	NULL
cells	NULL
&	NULL
I	NULL
1	NULL
36	NULL
62	NULL
Relative	NULL
fluorescence	NULL
intensity	NULL
(	NULL
logarithmic	NULL
scale	NULL
)	NULL
Figure	NULL
1	NULL
-	NULL
Commitment	NULL
of	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
towards	NULL
granulocytic	NULL
lineage	NULL
upon	NULL
DMSO	NULL
treatment	NULL
Profiles	NULL
represent	NULL
the	NULL
cell-surface	NULL
expression	NULL
of	NULL
CD11b	NULL
differentiation	NULL
antigen	NULL
during	NULL
DMSO-induced	NULL
celt	NULL
differentiation	NULL
.	NULL

HL-60	NULL
cells	NULL
were	NULL
cultured	NULL
as	NULL
described	NULL
below	NULL
and	NULL
then	NULL
chilled	NULL
at	NULL
4	NULL
°C	NULL
,	NULL
labelled	NULL
with	NULL
anti-CD11b	NULL
monoclonal	NULL
antibody	NULL
and	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
anti-mouse	NULL
IgG	NULL
and	NULL
subjected	NULL
to	NULL
immunofluorescence	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
in	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

(	NULL
@	NULL
)	NULL
Profiles	NULL
of	NULL
untreated	NULL
HL-60	NULL
cells	NULL
(	NULL
left	NULL
)	NULL
and	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
72	NULL
h	NULL
(	NULL
right	NULL
)	NULL
.	NULL

(	NULL
b	NULL
,	NULL
left	NULL
)	NULL
Profiles	NULL
of	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
6	NULL
h	NULL
,	NULL
24	NULL
h	NULL
and	NULL
48	NULL
h	NULL
and	NULL
then	NULL
labelled	NULL
with	NULL
anti-CD11b	NULL
monoclonal	NULL
antibody	NULL
.	NULL

(	NULL
b	NULL
,	NULL
right	NULL
)	NULL
Profiles	NULL
of	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
6	NULL
,	NULL
24	NULL
and	NULL
48	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
removal	NULL
of	NULL
DMSO	NULL
through	NULL
successive	NULL
washes	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
cultured	NULL
for	NULL
up	NULL
to	NULL
72	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
DMSO	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
,	NULL
and	NULL
then	NULL
labelled	NULL
with	NULL
anti-CD11b	NULL
monoclonal	NULL
antibody	NULL
.	NULL

The	NULL
percentages	NULL
of	NULL
CD11b-positive	NULL
cells	NULL
are	NULL
shown	NULL
in	NULL
the	NULL
upper	NULL
right	NULL
part	NULL
of	NULL
each	NULL
profile	NULL
.	NULL

Data	NULL
correspond	NULL
to	NULL
a	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
performed	NULL
.	NULL

The	NULL
vertical	NULL
broken	NULL
lines	NULL
represent	NULL
the	NULL
threshold	NULL
to	NULL
calculate	NULL
the	NULL
percentage	NULL
of	NULL
positive	NULL
cells	NULL
.	NULL

140	NULL
F.	NULL
Mollinedo	NULL
and	NULL
others	NULL
Period	NULL
of	NULL
treatment	NULL
with	NULL
PMA	NULL
...	NULL
0	NULL
min	NULL
10	NULL
min	NULL
30	NULL
min	NULL
-	NULL
1h	NULL
6	NULL
h	NULL
24h	NULL
c-fos	NULL
-	NULL
»	NULL
jun	NULL
B	NULL
-¥	NULL
»	NULL
18	NULL
§	NULL
-*	NULL
»	NULL
Figure	NULL
2	NULL
-	NULL
Expression	NULL
of	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
proto-oncogenes	NULL
in	NULL
PMA-treated	NULL
HL-60	NULL
cells	NULL
Northern-blot	NULL
analysis	NULL
of	NULL
mRNA	NULL
levels	NULL
after	NULL
cell	NULL
treatment	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
10	NULL
min	NULL
,	NULL
30	NULL
min	NULL
,	NULL
1	NULL
h	NULL
,	NULL
6	NULL
h	NULL
and	NULL
24	NULL
h.	NULL
Basal	NULL
control	NULL
levels	NULL
in	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
are	NULL
also	NULL
shown	NULL
(	NULL
first	NULL
lane	NULL
,	NULL
left	NULL
)	NULL
.	NULL

Ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
same	NULL
ge	NULL
!	NULL

reveals	NULL
equivalent	NULL
amounts	NULL
of	NULL
ribosomal	NULL
RNA	NULL
(	NULL
18	NULL
S	NULL
)	NULL
.	NULL

Autoradiograms	NULL
were	NULL
developed	NULL
after	NULL
24	NULL
h	NULL
of	NULL
exposure	NULL
.	NULL

For	NULL
further	NULL
details	NULL
,	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

(	NULL
a	NULL
)	NULL
(	NULL
b	NULL
)	NULL
(	NULL
c	NULL
)	NULL
PMA	NULL
(	NULL
6	NULL
h	NULL
)	NULL
a	NULL
<	NULL
©	NULL
(	NULL
+	NULL
]	NULL
it	NULL
PMA	NULL
DMSO	NULL
E3	NULL
I	NULL
1	NULL
b	NULL
1	NULL
<	NULL
I	NULL
0	NULL
1h	NULL
3h	NULL
6h	NULL
24h	NULL
0	NULL
1h	NULL
3h	NULL
6h	NULL
24h	NULL
wal	NULL
>	NULL
%	NULL
\	NULL
>	NULL
-	NULL
»	NULL
@	NULL
w	NULL
@	NULL
00	NULL
...	NULL
...	NULL
--	NULL
dibidd	NULL
-	NULL
-~	NULL
AA	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
Figure	NULL
3	NULL
-	NULL
Comparison	NULL
of	NULL
binding	NULL
to	NULL
an	NULL
AP-1	NULL
sequence	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
PMA-	NULL
and	NULL
DMSO-treated	NULL
HL-60	NULL
cells	NULL
(	NULL
a	NULL
)	NULL
Gel-retardation	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
20	NULL
ng/ml	NULL
PMA	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
3	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
6	NULL
h	NULL
(	NULL
Jane	NULL
4	NULL
)	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Gel-retardation	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
and	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1.3	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
DMSO	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
3	NULL
h	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
6	NULL
h	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

(	NULL
e	NULL
)	NULL
Binding	NULL
inhibition	NULL
using	NULL
the	NULL
specific	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
)	NULL
antibody	NULL
(	NULL
'	NULL
Anti-Fos	NULL
Ab	NULL
``	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
20	NULL
ng/m	NULL
!	NULL

PMA	NULL
for	NULL
6	NULL
h	NULL
were	NULL
incubated	NULL
with	NULL
preimmune	NULL
serum	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
or	NULL
with	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
)	NULL
antibody	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
,	NULL
and	NULL
then	NULL
tested	NULL
for	NULL
AP-1	NULL
binding	NULL
capacity	NULL
.	NULL

The	NULL
arrowhead	NULL
points	NULL
to	NULL
the	NULL
specific	NULL
binding	NULL
complex	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
.	NULL

The	NULL
arrow	NULL
points	NULL
to	NULL
the	NULL
free	NULL
oligoprobe	NULL
containing	NULL
the	NULL
consensus	NULL
AP-1	NULL
site	NULL
.	NULL

For	NULL
further	NULL
details	NULL
,	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

recently	NULL
described	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
mRNA	NULL
after	NULL
6-24	NULL
h	NULL
after	NULL
DMSO	NULL
addition	NULL
[	NULL
28	NULL
]	NULL
.	NULL

Binding	NULL
to	NULL
the	NULL
AP-1	NULL
recognition	NULL
site	NULL
during	NULL
PMA-	NULL
and	NULL
DMSO-induced	NULL
HL-60-cell	NULL
differentiation	NULL
We	NULL
detected	NULL
an	NULL
appreciable	NULL
AP-1	NULL
activity	NULL
in	NULL
untreated	NULL
HL-60	NULL
cells	NULL
by	NULL
gel-retardation	NULL
analysis	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

This	NULL
AP-1	NULL
activity	NULL
was	NULL
rapidly	NULL
increased	NULL
along	NULL
the	NULL
incubation	NULL
time	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
PMA	NULL
(	NULL
Figure	NULL
3a	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
AP-1	NULL
activity	NULL
detected	NULL
in	NULL
untreated	NULL
cells	NULL
disappeared	NULL
progressively	NULL
during	NULL
DMSO	NULL
treatment	NULL
(	NULL
Figure	NULL
3b	NULL
)	NULL
.	NULL

Competition	NULL
experiments	NULL
were	NULL
performed	NULL
to	NULL
identify	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
binding	NULL
complexes	NULL
.	NULL

Addition	NULL
of	NULL
a	NULL
50-fold	NULL
molar	NULL
excess	NULL
of	NULL
an	NULL
unlabelled	NULL
competitor	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
AP-1	NULL
site	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
resulted	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
bound	NULL
labelled	NULL
oligonucleotide	NULL
,	NULL
whereas	NULL
competition	NULL
with	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
CRE	NULL
(	NULL
cyclic	NULL
AMP-responsive	NULL
element	NULL
)	NULL
site	NULL
[	NULL
51	NULL
]	NULL
,	NULL
identical	NULL
with	NULL
the	NULL
AP-1	NULL
site	NULL
except	NULL
for	NULL
one	NULL
nucleotide	NULL
,	NULL
showed	NULL
no	NULL
effect	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
confirmed	NULL
with	NULL
specific	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
)	NULL
antibody	NULL
that	NULL
the	NULL
DNA-binding	NULL
complex	NULL
required	NULL
the	NULL
presence	NULL
of	NULL
Fos	NULL
protein	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

(	NULL
a	NULL
)	NULL
(	NULL
b	NULL
)	NULL
Sodium	NULL
butyrate	NULL
(	NULL
3	NULL
h	NULL
)	NULL
Po-	NULL
--	NULL
I	NULL
Sodium	NULL
butyrate	NULL
po	NULL
_	NULL
f	NULL
ot	NULL
Ot	NULL
oa	NULL
fede	NULL
men	NULL
0	NULL
1h	NULL
3h	NULL
6h	NULL
24h	NULL
+Anti-Fos	NULL
Ab	NULL
-	NULL
-	NULL
©	NULL
@	NULL
©es	NULL
:	NULL
u	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
Figure	NULL
4	NULL
Binding	NULL
to	NULL
an	NULL
AP-1	NULL
sequence	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
sodium	NULL
butyrate-treated	NULL
HL-60	NULL
cells	NULL
(	NULL
a	NULL
)	NULL
Gel-retardation	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
untreated	NULL
HL-60	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
3	NULL
mM	NULL
sodium	NULL
butyrate	NULL
for	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
3	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
6	NULL
h	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Binding	NULL
inhibition	NULL
using	NULL
the	NULL
specific	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
)	NULL
antibody	NULL
(	NULL
'Anti-Fos	NULL
Ab	NULL
'	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
3	NULL
mM	NULL
sodium	NULL
butyrate	NULL
for	NULL
3	NULL
h	NULL
were	NULL
incubated	NULL
with	NULL
preimmune	NULL
serum	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
or	NULL
with	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
)	NULL
antibody	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
and	NULL
then	NULL
tested	NULL
for	NULL
AP-1	NULL
binding	NULL
capacity	NULL
.	NULL

The	NULL
DNA-binding	NULL
complex	NULL
(	NULL
arrowhead	NULL
)	NULL
and	NULL
the	NULL
free	NULL
oligoprabe	NULL
containing	NULL
the	NULL
consensus	NULL
AP-1	NULL
site	NULL
(	NULL
arrow	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

For	NULL
further	NULL
details	NULL
,	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

AP-1	NULL
activity	NULL
during	NULL
myeloid	NULL
differentiation	NULL
141	NULL
(	NULL
a	NULL
)	NULL
(	NULL
b	NULL
)	NULL
(	NULL
c	NULL
)	NULL
Vit	NULL
.	NULL

D	NULL
;	NULL
(	NULL
6	NULL
h	NULL
)	NULL
2	NULL
Fe	NULL
Pa	NULL
o	NULL
if	NULL
RA	NULL
Vit	NULL
.	NULL

D	NULL
;	NULL
€	NULL
r	NULL
1	NULL
r	NULL
1	NULL
<	NULL
I	NULL
0	NULL
2h6h24	NULL
h	NULL
0	NULL
2h	NULL
6h	NULL
24	NULL
h	NULL
*	NULL
>	NULL
is	NULL
po	NULL
ae	NULL
14	NULL
pws	NULL
to	NULL
to	NULL
>	NULL
Wwi	NULL
#	NULL
-	NULL
»	NULL
-Atte	NULL
-	NULL
AA	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
10	NULL
9	NULL
Figure	NULL
5	NULL
-	NULL
Comparison	NULL
of	NULL
binding	NULL
to	NULL
an	NULL
AP-1	NULL
sequence	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
retinoic	NULL
acid-	NULL
and	NULL
1	NULL
«	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
-treated	NULL
HL-60	NULL
cells	NULL
(	NULL
a	NULL
)	NULL
Gel-retardation	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
and	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1	NULL
M	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
for	NULL
2	NULL
h	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
6	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Gel-retardation	NULL
analysis	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
(	NULL
fane	NULL
5	NULL
)	NULL
and	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
1078	NULL
M	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
(	NULL
Vit	NULL
.	NULL

D	NULL
;	NULL
)	NULL
for	NULL
2	NULL
h	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
6	NULL
h	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

(	NULL
¢	NULL
)	NULL
Binding	NULL
inhibition	NULL
using	NULL
the	NULL
specific	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
)	NULL
antibody	NULL
(	NULL
'Anti-Fos	NULL
Ab	NULL
``	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
HL-60	NULL
ceils	NULL
treated	NULL
with	NULL
1078	NULL
M	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
for	NULL
6	NULL
h	NULL
were	NULL
incubated	NULL
with	NULL
preimmune	NULL
serum	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
or	NULL
with	NULL
anti-Fos	NULL
M	NULL
antibody	NULL
(	NULL
lane	NULL
10	NULL
)	NULL
,	NULL
and	NULL
then	NULL
tested	NULL
for	NULL
AP-1	NULL
binding	NULL
capacity	NULL
.	NULL

The	NULL
DNA-binding	NULL
complex	NULL
(	NULL
arrowhead	NULL
)	NULL
and	NULL
the	NULL
free	NULL
oligoprobe	NULL
containing	NULL
the	NULL
AP-1	NULL
site	NULL
(	NULL
arrow	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

For	NULL
further	NULL
details	NULL
,	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

Sodium	NULL
butyrate	NULL
0	NULL
30min	NULL
lh	NULL
2h	NULL
4h	NULL
24h	NULL
28	NULL
S	NULL
c-fos	NULL
-	NULL
»	NULL
18	NULL
S	NULL
as	NULL
w	NULL
»	NULL
s	NULL
28	NULL
S	NULL
c-jun	NULL
-	NULL
»	NULL
18	NULL
S	NULL
Effect	NULL
of	NULL
other	NULL
inducers	NULL
of	NULL
myeloid	NULL
differentiation	NULL
on	NULL
AP-1	NULL
binding	NULL
activity	NULL
Treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
3	NULL
mM	NULL
sodium	NULL
butyrate	NULL
,	NULL
an	NULL
inducer	NULL
of	NULL
monocytic	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
[	NULL
2,6	NULL
]	NULL
,	NULL
resulted	NULL
in	NULL
a	NULL
rapid	NULL
and	NULL
transient	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
(	NULL
Figure	NULL
4a	NULL
)	NULL
.	NULL

Using	NULL
the	NULL
specific	NULL
anti-	NULL
(	NULL
Fos	NULL
M	NULL
)	NULL
antibody	NULL
,	NULL
we	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
Fos/AP-1	NULL
complex	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
(	NULL
Figure	NULL
4b	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
10°	NULL
M	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
,	NULL
another	NULL
monocytic	NULL
HL-60	NULL
differentiating	NULL
agent	NULL
[	NULL
2,7	NULL
]	NULL
,	NULL
induced	NULL
a	NULL
weak	NULL
,	NULL
but	NULL
appreciable	NULL
,	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
,	NULL
which	NULL
required	NULL
Fos	NULL
protein	NULL
(	NULL
Figure	NULL
5c	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
HL-60	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
1	NULL
«	NULL
M	NULL
retinoic	NULL
acid	NULL
,	NULL
an	NULL
inducer	NULL
of	NULL
granulocytic	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
[	NULL
2,4	NULL
]	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
observed	NULL
(	NULL
Figure	NULL
Sa	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
fos	NULL
and	NULL
jun	NULL
proto-oncogenes	NULL
during	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
sodium	NULL
butyrate	NULL
,	NULL
1	NULL
«	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
or	NULL
retinole	NULL
acid	NULL
As	NULL
sodium	NULL
butyrate	NULL
induced	NULL
a	NULL
rapid	NULL
and	NULL
remarkable	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
,	NULL
we	NULL
analysed	NULL
the	NULL
effect	NULL
of	NULL
this	NULL
monocytic	NULL
differentiation	NULL
agent	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
fos	NULL
and	NULL
jun	NULL
proto-oncogenes	NULL
in	NULL
HL-60	NULL
cells	NULL
.	NULL

Addition	NULL
of	NULL
sodium	NULL
butyrate	NULL
to	NULL
HL-60	NULL
cells	NULL
induced	NULL
a	NULL
rapid	NULL
and	NULL
sustained	NULL
increase	NULL
in	NULL
the	NULL
2.2	NULL
kb	NULL
c-fos	NULL
mRNA	NULL
level	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

A	NULL
detailed	NULL
time	NULL
course	NULL
showed	NULL
that	NULL
the	NULL
c-fos	NULL
mRNA	NULL
level	NULL
was	NULL
elevated	NULL
as	NULL
early	NULL
as	NULL
30	NULL
min	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
sodium	NULL
butyrate	NULL
,	NULL
reaching	NULL
its	NULL
maximum	NULL
at	NULL
24	NULL
h	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
major	NULL
2.2	NULL
kb	NULL
band	NULL
,	NULL
a	NULL
weak	NULL
hybridization	NULL
band	NULL
of	NULL
about	NULL
2.0	NULL
kb	NULL
was	NULL
visible	NULL
,	NULL
presumably	NULL
related	NULL
to	NULL
r-fos	NULL
gene	NULL
transcripts	NULL
[	NULL
31	NULL
]	NULL
.	NULL

The	NULL
faint	NULL
band	NULL
at	NULL
about	NULL
3.5	NULL
kb	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
represent	NULL
an	NULL
unprocessed	NULL
transcript	NULL
[	NULL
31	NULL
]	NULL
.	NULL

Addition	NULL
of	NULL
sodium	NULL
butyrate	NULL
to	NULL
HL-60	NULL
cells	NULL
resulted	NULL
in	NULL
a	NULL
Sodium	NULL
butyrate	NULL
po	NULL
4	NULL
0	NULL
30	NULL
min	NULL
1h	NULL
2h	NULL
4h	NULL
24h	NULL
28	NULL
S	NULL
jun	NULL
B	NULL
-	NULL
>	NULL
wa	NULL
18	NULL
5	NULL
0	NULL
-	NULL
e	NULL
#	NULL
28	NULL
S	NULL
Figure	NULL
6	NULL
-	NULL
Expression	NULL
of	NULL
c-fos	NULL
,	NULL
c-/un	NULL
,	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
in	NULL
sodium	NULL
butyrate-treated	NULL
HL-60	NULL
cells	NULL
Northern-blot	NULL
analysis	NULL
of	NULL
mRNA	NULL
tevels	NULL
after	NULL
cell	NULL
treatment	NULL
with	NULL
sodium	NULL
butyrate	NULL
(	NULL
3	NULL
mM	NULL
)	NULL
for	NULL
30	NULL
min	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
2	NULL
h	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
4	NULL
h	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Basal	NULL
control	NULL
levels	NULL
in	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
are	NULL
also	NULL
shown	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
same	NULL
gel	NULL
reveals	NULL
equivalent	NULL
amounts	NULL
of	NULL
ribosomal	NULL
RNA	NULL
{	NULL
middle	NULL
of	NULL
the	NULL
Figure	NULL
)	NULL
.	NULL

Autoradiograms	NULL
were	NULL
developed	NULL
after	NULL
24-48	NULL
h	NULL
of	NULL
exposure	NULL
.	NULL

For	NULL
further	NULL
details	NULL
,	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

142	NULL
F.	NULL
Mollinedo	NULL
and	NULL
others	NULL
Vit	NULL
.	NULL

D	NULL
;	NULL
Vit	NULL
.	NULL

D	NULL
;	NULL
pod	NULL
ro	NULL
-d	NULL
0	NULL
4h	NULL
24h	NULL
0	NULL
4h	NULL
24h	NULL
28	NULL
S	NULL
-	NULL
28	NULL
S	NULL
c-fos	NULL
-	NULL
»	NULL
0	NULL
18Ss-	NULL
jun	NULL
B	NULL
-	NULL
»	NULL
Q	NULL
``	NULL
``	NULL
~	NULL
%	NULL
28	NULL
S	NULL
-	NULL
28	NULL
S	NULL
c-jun	NULL
-	NULL
»	NULL
’	NULL
<	NULL
-	NULL
»	NULL
00	NULL
18S	NULL
-	NULL
18	NULL
S-	NULL
*	NULL
1	NULL
2	NULL
3	NULL
1	NULL
2	NULL
3	NULL
Figure	NULL
7	NULL
-	NULL
Expression	NULL
of	NULL
c-fos	NULL
,	NULL
c-/un	NULL
,	NULL
Jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
in	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
-treated	NULL
HL-60	NULL
cells	NULL
Northern-blot	NULL
analysis	NULL
of	NULL
mRNA	NULL
levels	NULL
after	NULL
cell	NULL
treatment	NULL
with	NULL
10-8	NULL
M	NULL
1a,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
(	NULL
Vit	NULL
.	NULL

D	NULL
;	NULL
)	NULL
for	NULL
4	NULL
h	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Basal	NULL
control	NULL
levels	NULL
in	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
are	NULL
also	NULL
shown	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
same	NULL
ge	NULL
!	NULL

reveals	NULL
equivalent	NULL
amounts	NULL
of	NULL
ribosomal	NULL
RNA	NULL
(	NULL
bottom	NULL
of	NULL
the	NULL
Figure	NULL
)	NULL
.	NULL

Autoradiograms	NULL
were	NULL
developed	NULL
after	NULL
24-48	NULL
h	NULL
of	NULL
exposure	NULL
.	NULL

For	NULL
further	NULL
details	NULL
,	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

rapid	NULL
increase	NULL
in	NULL
the	NULL
2.1	NULL
kb	NULL
jun	NULL
B	NULL
mRNA	NULL
level	NULL
after	NULL
30	NULL
min	NULL
treatment	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
highest	NULL
jur	NULL
B	NULL
mRNA	NULL
induction	NULL
was	NULL
achieved	NULL
after	NULL
24	NULL
h	NULL
of	NULL
sodium	NULL
butyrate	NULL
addition	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
c-jun	NULL
and	NULL
jun	NULL
D	NULL
mRNA	NULL
were	NULL
practically	NULL
unchanged	NULL
during	NULL
the	NULL
first	NULL
4	NULL
h	NULL
of	NULL
sodium	NULL
butyrate	NULL
treatment	NULL
,	NULL
but	NULL
a	NULL
remarkable	NULL
increase	NULL
in	NULL
the	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
of	NULL
both	NULL
proto-oncogenes	NULL
was	NULL
observed	NULL
after	NULL
24	NULL
h	NULL
after	NULL
sodium	NULL
butyrate	NULL
addition	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

The	NULL
size	NULL
of	NULL
the	NULL
c-jur	NULL
mRNA	NULL
was	NULL
about	NULL
2.7	NULL
kb	NULL
,	NULL
as	NULL
had	NULL
already	NULL
been	NULL
reported	NULL
[	NULL
11,12	NULL
]	NULL
.	NULL

A	NULL
minor	NULL
band	NULL
of	NULL
about	NULL
3.4	NULL
kb	NULL
,	NULL
suggested	NULL
to	NULL
be	NULL
a	NULL
precursor	NULL
molecule	NULL
[	NULL
11,12	NULL
]	NULL
,	NULL
was	NULL
also	NULL
evident	NULL
after	NULL
overexposure	NULL
of	NULL
the	NULL
autoradiogram	NULL
.	NULL

The	NULL
size	NULL
of	NULL
jun	NULL
D	NULL
transcript	NULL
was	NULL
about	NULL
2.0	NULL
kb	NULL
,	NULL
also	NULL
as	NULL
already	NULL
reported	NULL
[	NULL
24	NULL
]	NULL
.	NULL

Addition	NULL
of	NULL
1	NULL
«	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
to	NULL
HL-60	NULL
cell	NULL
cultures	NULL
resulted	NULL
also	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
steady-state	NULL
mRNA	NULL
levels	NULL
of	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

However	NULL
,	NULL
exposure	NULL
of	NULL
HL-60	NULL
cells	NULL
to	NULL
retinoic	NULL
acid	NULL
did	NULL
not	NULL
induce	NULL
any	NULL
accumulation	NULL
of	NULL
c-fos	NULL
,	NULL
c-jun	NULL
or	NULL
jun	NULL
B	NULL
transcripts	NULL
(	NULL
results	NULL
not	NULL
RA	NULL
l	NULL
1	NULL
0	NULL
30	NULL
min	NULL
1h	NULL
6h	NULL
24h	NULL
48	NULL
h	NULL
28	NULL
S	NULL
jun	NULL
D	NULL
-	NULL
»	NULL
g	NULL
Q	NULL
Q	NULL
ﬂ	NULL
18s	NULL
°	NULL
‘	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
28	NULL
S	NULL
18	NULL
S	NULL
»	NULL
Figure	NULL
8	NULL
Expression	NULL
of	NULL
jun	NULL
D	NULL
proto-oncogene	NULL
in	NULL
retinoic	NULL
acid-treated	NULL
HL-60	NULL
ceils	NULL
Northern-blot	NULL
analysis	NULL
of	NULL
mRNA	NULL
levels	NULL
after	NULL
cell	NULL
treatment	NULL
with	NULL
1	NULL
M	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
for	NULL
30	NULL
min	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
1	NULL
h	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
6	NULL
h	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
24	NULL
h	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
and	NULL
48	NULL
h	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Basal	NULL
control	NULL
level	NULL
of	NULL
jun	NULL
D	NULL
mRNA	NULL
in	NULL
uninduced	NULL
HL-60	NULL
cells	NULL
is	NULL
also	NULL
shown	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
same	NULL
ge	NULL
!	NULL

reveals	NULL
equivalent	NULL
amounts	NULL
of	NULL
ribosomal	NULL
RNA	NULL
.	NULL

The	NULL
autoradiogram	NULL
was	NULL
developed	NULL
after	NULL
48	NULL
h	NULL
of	NULL
exposure	NULL
.	NULL

For	NULL
further	NULL
details	NULL
,	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
methods	NULL
section	NULL
.	NULL

shown	NULL
)	NULL
.	NULL

Only	NULL
the	NULL
jur	NULL
D	NULL
mRNA	NULL
level	NULL
was	NULL
weakly	NULL
increased	NULL
by	NULL
retinoic	NULL
acid	NULL
treatment	NULL
(	NULL
Figure	NULL
8	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Incubation	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
for	NULL
30-60	NULL
min	NULL
or	NULL
with	NULL
DMSO	NULL
for	NULL
24	NULL
h	NULL
is	NULL
sufficient	NULL
to	NULL
commit	NULL
the	NULL
cells	NULL
towards	NULL
macrophage	NULL
or	NULL
granulocytic	NULL
differentiation	NULL
respectively	NULL
,	NULL
although	NULL
complete	NULL
cell	NULL
differentiation	NULL
shows	NULL
up	NULL
much	NULL
later	NULL
(	NULL
24	NULL
h	NULL
and	NULL
7	NULL
days	NULL
for	NULL
full	NULL
macrophage	NULL
and	NULL
granulocytic	NULL
differentiation	NULL
respectively	NULL
)	NULL
.	NULL

The	NULL
results	NULL
herein	NULL
reported	NULL
demonstrate	NULL
for	NULL
the	NULL
first	NULL
time	NULL
that	NULL
a	NULL
distinct	NULL
expression	NULL
of	NULL
the	NULL
AP-1	NULL
transcription	NULL
factor	NULL
takes	NULL
place	NULL
during	NULL
macrophage	NULL
and	NULL
granulocytic	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
.	NULL

This	NULL
conclusion	NULL
is	NULL
based	NULL
on	NULL
the	NULL
examination	NULL
of	NULL
AP-1	NULL
expression	NULL
at	NULL
the	NULL
mRNA	NULL
level	NULL
as	NULL
well	NULL
as	NULL
on	NULL
the	NULL
functional	NULL
AP-1	NULL
activity	NULL
assessed	NULL
by	NULL
gel-retardation	NULL
analysis	NULL
.	NULL

Northern-blot	NULL
analysis	NULL
showed	NULL
that	NULL
jur	NULL
B	NULL
and	NULL
c-fos	NULL
mRNA	NULL
levels	NULL
were	NULL
highly	NULL
increased	NULL
during	NULL
the	NULL
commitment	NULL
of	NULL
PMA-induced	NULL
HL-60	NULL
macrophage	NULL
differentiation	NULL
,	NULL
occurring	NULL
during	NULL
the	NULL
first	NULL
30-60	NULL
min	NULL
of	NULL
PMA	NULL
treatment	NULL
.	NULL

After	NULL
that	NULL
time	NULL
,	NULL
the	NULL
level	NULL
of	NULL
c-fos	NULL
transcripts	NULL
diminished	NULL
,	NULL
but	NULL
appreciable	NULL
levels	NULL
of	NULL
c-fos	NULL
transcripts	NULL
could	NULL
be	NULL
detected	NULL
,	NULL
even	NULL
after	NULL
24	NULL
h	NULL
of	NULL
PMA	NULL
treatment	NULL
(	NULL
see	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

The	NULL
content	NULL
of	NULL
jun	NULL
B	NULL
mRNA	NULL
remained	NULL
at	NULL
high	NULL
levels	NULL
throughout	NULL
the	NULL
PMA	NULL
incubation	NULL
time	NULL
assayed	NULL
(	NULL
from	NULL
30	NULL
min	NULL
to	NULL
24	NULL
h	NULL
)	NULL
(	NULL
see	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
PMA	NULL
treatment	NULL
induces	NULL
expression	NULL
of	NULL
jun	NULL
B	NULL
in	NULL
conjunction	NULL
with	NULL
c-fos	NULL
suggests	NULL
that	NULL
both	NULL
Jun-Jun	NULL
and	NULL
Jun-Fos	NULL
AP-1	NULL
activity	NULL
during	NULL
myeloid	NULL
differentiation	NULL
143	NULL
complexes	NULL
can	NULL
be	NULL
formed	NULL
during	NULL
the	NULL
commitment	NULL
stage	NULL
of	NULL
PMA-induced	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
.	NULL

The	NULL
AP-1	NULL
binding	NULL
activity	NULL
rapidly	NULL
increased	NULL
after	NULL
PMA	NULL
addition	NULL
,	NULL
and	NULL
a	NULL
remarkable	NULL
AP-1	NULL
activity	NULL
was	NULL
observed	NULL
after	NULL
24	NULL
h	NULL
of	NULL
PMA	NULL
treatment	NULL
.	NULL

Thus	NULL
we	NULL
observed	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
nucleoprotein	NULL
complex	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
during	NULL
the	NULL
commitment	NULL
of	NULL
macrophage	NULL
differentiation	NULL
as	NULL
well	NULL
as	NULL
in	NULL
fully	NULL
differentiated	NULL
HL-60	NULL
macrophages	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
can	NULL
be	NULL
important	NULL
in	NULL
the	NULL
commitment	NULL
to	NULL
the	NULL
PMA-induced	NULL
macrophage	NULL
differentiation	NULL
and	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
mature	NULL
macrophages	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
in	NULL
spite	NULL
of	NULL
an	NULL
early	NULL
,	NULL
though	NULL
small	NULL
and	NULL
transient	NULL
,	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
c-jun	NULL
transcripts	NULL
during	NULL
PMA-induced	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
,	NULL
maximal	NULL
induction	NULL
of	NULL
c-jur	NULL
mRNA	NULL
level	NULL
was	NULL
observed	NULL
in	NULL
terminally	NULL
PMA-differentiated	NULL
HL-60	NULL
macrophages	NULL
[	NULL
28,35,36	NULL
]	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
reported	NULL
the	NULL
late	NULL
expression	NULL
of	NULL
both	NULL
c-jun	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
during	NULL
PMA-induced	NULL
HL-60	NULL
macrophage	NULL
differentiation	NULL
[	NULL
28	NULL
]	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
c-jun	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
can	NULL
be	NULL
mainly	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
the	NULL
late	NULL
stages	NULL
of	NULL
macrophage	NULL
differentiation	NULL
or	NULL
in	NULL
terminally	NULL
differentiated	NULL
macrophages	NULL
rather	NULL
than	NULL
in	NULL
the	NULL
commitment	NULL
of	NULL
macrophage	NULL
differentiation	NULL
,	NULL
when	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
are	NULL
actively	NULL
expressed	NULL
.	NULL

The	NULL
results	NULL
herein	NULL
reported	NULL
indicate	NULL
for	NULL
the	NULL
first	NULL
time	NULL
the	NULL
disappearance	NULL
of	NULL
the	NULL
AP-1	NULL
activity	NULL
detected	NULL
in	NULL
untreated	NULL
cells	NULL
during	NULL
the	NULL
commitment	NULL
of	NULL
granulocytic	NULL
HL-60	NULL
differentiation	NULL
induced	NULL
by	NULL
DMSO	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
no	NULL
accumulation	NULL
of	NULL
c-jun	NULL
and	NULL
c-fos	NULL
transcripts	NULL
was	NULL
observed	NULL
during	NULL
granulocytic	NULL
HL-60	NULL
differentiation	NULL
induced	NULL
by	NULL
DMSO	NULL
[	NULL
28,31,36	NULL
]	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
have	NULL
found	NULL
an	NULL
increase	NULL
in	NULL
Jun-immunoreactive	NULL
protein	NULL
during	NULL
DMSO	NULL
treatment	NULL
(	NULL
F.	NULL
Mollinedo	NULL
and	NULL
J.	NULL
R.	NULL
Naranjo	NULL
,	NULL
unpublished	NULL
work	NULL
)	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
Jun-immunoreactive	NULL
protein	NULL
is	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
Jun	NULL
B	NULL
and	NULL
Jun	NULL
D	NULL
proteins	NULL
,	NULL
since	NULL
we	NULL
have	NULL
previously	NULL
reported	NULL
[	NULL
28	NULL
]	NULL
that	NULL
the	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
,	NULL
but	NULL
not	NULL
c-jun	NULL
,	NULL
mRNA	NULL
levels	NULL
are	NULL
increased	NULL
during	NULL
DMSO	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
[	NULL
28	NULL
]	NULL
.	NULL

The	NULL
disappearance	NULL
of	NULL
the	NULL
basal	NULL
AP-1	NULL
binding	NULL
activity	NULL
during	NULL
DMSO	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
could	NULL
be	NULL
consistent	NULL
with	NULL
our	NULL
previous	NULL
data	NULL
describing	NULL
the	NULL
induction	NULL
of	NULL
jur	NULL
B	NULL
and	NULL
jur	NULL
D	NULL
proto-oncogenes	NULL
during	NULL
DMSO	NULL
treatment	NULL
[	NULL
28	NULL
]	NULL
.	NULL

Jun	NULL
B	NULL
and	NULL
Jun	NULL
D	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
c-Fos	NULL
,	NULL
bind	NULL
to	NULL
the	NULL
AP-1	NULL
oligonucleotide	NULL
very	NULL
poorly	NULL
[	NULL
29	NULL
]	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
increased	NULL
levels	NULL
of	NULL
Jun	NULL
proteins	NULL
,	NULL
other	NULL
than	NULL
c-Jun	NULL
,	NULL
could	NULL
*squelch	NULL
'	NULL
the	NULL
formation	NULL
of	NULL
functional	NULL
c-Fos/c-Jun	NULL
heterodimers	NULL
and	NULL
contribute	NULL
to	NULL
reducing	NULL
the	NULL
basal	NULL
AP-1	NULL
binding	NULL
activity	NULL
observed	NULL
in	NULL
untreated	NULL
HL-60	NULL
cells	NULL
by	NULL
gel-retardation	NULL
analysis	NULL
.	NULL

This	NULL
DMSO-induced	NULL
inhibitory	NULL
effect	NULL
on	NULL
AP-1	NULL
activity	NULL
could	NULL
also	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
degradation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
already	NULL
present	NULL
in	NULL
undifferentiated	NULL
HL-60	NULL
cells	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
differentiation	NULL
of	NULL
HL-60	NULL
cells	NULL
towards	NULL
granulocytes	NULL
upon	NULL
DMSO	NULL
treatment	NULL
.	NULL

Accumulating	NULL
evidence	NULL
indicates	NULL
that	NULL
protein	NULL
dimerization	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
transcriptional	NULL
regulation	NULL
[	NULL
52	NULL
]	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
three	NULL
members	NULL
of	NULL
the	NULL
Jun	NULL
family	NULL
are	NULL
able	NULL
to	NULL
form	NULL
homodimers	NULL
as	NULL
well	NULL
as	NULL
heterodimers	NULL
with	NULL
each	NULL
of	NULL
the	NULL
other	NULL
Jun	NULL
proteins	NULL
,	NULL
leading	NULL
to	NULL
binding	NULL
to	NULL
an	NULL
AP-1	NULL
site	NULL
in	NULL
DNA	NULL
,	NULL
and	NULL
that	NULL
this	NULL
AP-1	NULL
binding	NULL
is	NULL
highly	NULL
increased	NULL
by	NULL
interaction	NULL
of	NULL
each	NULL
Jun	NULL
protein	NULL
with	NULL
Fos	NULL
[	NULL
23,29	NULL
]	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
increase	NULL
in	NULL
c-fos	NULL
mRNA	NULL
level	NULL
during	NULL
DMSO	NULL
treatment	NULL
.	NULL

Thus	NULL
during	NULL
DMSO-induced	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
,	NULL
the	NULL
induced	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
proto-oncogenes	NULL
might	NULL
form	NULL
heterodimers	NULL
with	NULL
other	NULL
nuclear	NULL
proteins	NULL
,	NULL
showing	NULL
DNA-binding	NULL
specificities	NULL
different	NULL
from	NULL
the	NULL
AP-1	NULL
site	NULL
.	NULL

In	NULL
this	NULL
context	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
members	NULL
of	NULL
the	NULL
Fos/Jun	NULL
and	NULL
ATF/CREB	NULL
families	NULL
of	NULL
transcription	NULL
factors	NULL
can	NULL
form	NULL
selective	NULL
cross-family	NULL
heterodimers	NULL
with	NULL
distinguishable	NULL
DNA-binding	NULL
specificities	NULL
from	NULL
each	NULL
other	NULL
and	NULL
from	NULL
their	NULL
parental	NULL
homodimers	NULL
[	NULL
53	NULL
]	NULL
.	NULL

Unlike	NULL
DMSO-induced	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
,	NULL
macrophage	NULL
cell	NULL
differentiation	NULL
induced	NULL
by	NULL
PMA	NULL
resulted	NULL
in	NULL
a	NULL
rapid	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
,	NULL
suggesting	NULL
a	NULL
putative	NULL
role	NULL
for	NULL
transcription	NULL
factor	NULL
AP-1	NULL
in	NULL
macrophage	NULL
differentiation	NULL
.	NULL

It	NULL
has	NULL
been	NULL
recently	NULL
reported	NULL
that	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
increases	NULL
the	NULL
c-jun	NULL
mRNA	NULL
level	NULL
[	NULL
35,36	NULL
]	NULL
,	NULL
whereas	NULL
HL-60	NULL
cell	NULL
treatment	NULL
with	NULL
DMSO	NULL
or	NULL
retinoic	NULL
acid	NULL
does	NULL
not	NULL
alter	NULL
c-jun	NULL
expression	NULL
[	NULL
28,36	NULL
]	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
cyclic	NULL
AMP	NULL
analogues	NULL
or	NULL
with	NULL
agents	NULL
that	NULL
increase	NULL
intracellular	NULL
cyclic	NULL
AMP	NULL
levels	NULL
,	NULL
inducing	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
differentiated	NULL
monocytic	NULL
phenotype	NULL
,	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
rapid	NULL
increase	NULL
in	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
mRNA	NULL
levels	NULL
[	NULL
54,55	NULL
]	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
herein	NULL
report	NULL
that	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
sodium	NULL
butyrate	NULL
,	NULL
an	NULL
inducer	NULL
of	NULL
monocytic	NULL
HL-60	NULL
differentiation	NULL
,	NULL
promotes	NULL
rapid	NULL
increases	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
in	NULL
the	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
mRNA	NULL
levels	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
c-jun	NULL
and	NULL
jun	NULL
D	NULL
mRNA	NULL
were	NULL
also	NULL
elevated	NULL
after	NULL
24	NULL
h	NULL
of	NULL
sodium	NULL
butyrate	NULL
addition	NULL
.	NULL

These	NULL
effects	NULL
of	NULL
sodium	NULL
butyrate	NULL
on	NULL
AP-1	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
on	NULL
fos	NULL
and	NULL
jun	NULL
proto-oncogene	NULL
expression	NULL
in	NULL
HL-60	NULL
cells	NULL
resemble	NULL
those	NULL
induced	NULL
by	NULL
PMA	NULL
(	NULL
the	NULL
present	NULL
work	NULL
;	NULL
[	NULL
28	NULL
]	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
a	NULL
noteworthy	NULL
difference	NULL
resides	NULL
in	NULL
the	NULL
high	NULL
and	NULL
sustained	NULL
elevation	NULL
of	NULL
c-fos	NULL
mRNA	NULL
level	NULL
induced	NULL
by	NULL
sodium	NULL
butyrate	NULL
(	NULL
cf	NULL
.	NULL

Figures	NULL
2	NULL
and	NULL
6	NULL
)	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
treatment	NULL
of	NULL
PC12	NULL
phaeo-chromocytoma	NULL
cells	NULL
with	NULL
sodium	NULL
butyrate	NULL
results	NULL
in	NULL
stable	NULL
high	NULL
levels	NULL
of	NULL
c-fos	NULL
mRNA	NULL
[	NULL
56	NULL
]	NULL
.	NULL

We	NULL
have	NULL
also	NULL
found	NULL
that	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
the	NULL
monocytic	NULL
differentiating	NULL
agent	NULL
1	NULL
«	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
induced	NULL
an	NULL
increase	NULL
in	NULL
AP-1	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
an	NULL
elevation	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
c-fos	NULL
,	NULL
c-jun	NULL
,	NULL
jun	NULL
B	NULL
and	NULL
jun	NULL
D	NULL
mRNA	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
an	NULL
anti-Fos	NULL
antibody	NULL
blocked	NULL
the	NULL
AP-1	NULL
binding	NULL
activity	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
three	NULL
monocytic	NULL
differentiating	NULL
agents	NULL
used	NULL
(	NULL
PMA	NULL
,	NULL
sodium	NULL
butyrate	NULL
and	NULL
1	NULL
@	NULL
,25-dihydroxyvitamin	NULL
D	NULL
,	NULL
)	NULL
,	NULL
thus	NULL
demonstrating	NULL
that	NULL
the	NULL
AP-1	NULL
binding	NULL
activity	NULL
observed	NULL
was	NULL
caused	NULL
by	NULL
Fos/Jun	NULL
heterodimers	NULL
,	NULL
probably	NULL
c-Fos/Jun	NULL
B	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
there	NULL
was	NULL
a	NULL
correlation	NULL
between	NULL
the	NULL
increased	NULL
expression	NULL
of	NULL
c-fos	NULL
and	NULL
jun	NULL
B	NULL
proto-oncogenes	NULL
and	NULL
an	NULL
enhancement	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
activity	NULL
present	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
HL-60	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
three	NULL
monocytic	NULL
differentiation	NULL
inducers	NULL
used	NULL
in	NULL
the	NULL
present	NULL
study	NULL
at	NULL
early	NULL
times	NULL
of	NULL
incubation	NULL
.	NULL

However	NULL
,	NULL
this	NULL
correlation	NULL
was	NULL
lost	NULL
at	NULL
later	NULL
times	NULL
of	NULL
incubation	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
post-translational	NULL
control	NULL
mechanism	NULL
could	NULL
be	NULL
additionally	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
AP-1	NULL
activity	NULL
,	NULL
as	NULL
previously	NULL
suggested	NULL
[	NULL
49	NULL
]	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
treatment	NULL
of	NULL
HL-60	NULL
cells	NULL
with	NULL
retinoic	NULL
acid	NULL
,	NULL
a	NULL
granulocytic	NULL
differentiation	NULL
inducer	NULL
,	NULL
neither	NULL
enhances	NULL
AP-1	NULL
binding	NULL
activity	NULL
nor	NULL
modifies	NULL
the	NULL
basal	NULL
levels	NULL
of	NULL
c-fos	NULL
,	NULL
c-jun	NULL
or	NULL
jun	NULL
B	NULL
transcripts	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
retinoic	NULL
acid	NULL
behaved	NULL
similarly	NULL
to	NULL
DMSO	NULL
[	NULL
28	NULL
]	NULL
in	NULL
inducing	NULL
an	NULL
increase	NULL
of	NULL
the	NULL
jun	NULL
D	NULL
mRNA	NULL
level	NULL
when	NULL
added	NULL
to	NULL
HL-60	NULL
cells	NULL
.	NULL

As	NULL
no	NULL
increase	NULL
in	NULL
AP-1	NULL
binding	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
either	NULL
retinoic	NULL
acid-	NULL
or	NULL
DMSO-treated	NULL
cells	NULL
,	NULL
it	NULL
could	NULL
be	NULL
envisaged	NULL
that	NULL
transcriptional	NULL
complexes	NULL
involving	NULL
jun	NULL
D	NULL
gene	NULL
product	NULL
and	NULL
lacking	NULL
AP-1	NULL
activity	NULL
could	NULL
be	NULL
formed	NULL
during	NULL
granulocytic	NULL
HL-60	NULL
differentiation	NULL
.	NULL

On	NULL
these	NULL
grounds	NULL
it	NULL
could	NULL
be	NULL
envisaged	NULL
that	NULL
the	NULL
differential	NULL
induction	NULL
of	NULL
AP-1	NULL
activity	NULL
could	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
HL-60	NULL
cell	NULL
differentiation	NULL
towards	NULL
monocytic	NULL
or	NULL
granulocytic	NULL
lineages	NULL
.	NULL

Thus	NULL
an	NULL
increase	NULL
in	NULL
AP-1	NULL
activity	NULL
could	NULL
be	NULL
correlated	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
monocytic	NULL
differentiation	NULL
,	NULL
whereas	NULL
no	NULL
induction	NULL
,	NULL
or	NULL
even	NULL
inhibition	NULL
,	NULL
of	NULL
AP-1	NULL
activity	NULL
could	NULL
be	NULL
correlated	NULL
with	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
suggest	NULL
that	NULL
inhibition	NULL
of	NULL
AP-1	NULL
activity	NULL
could	NULL
favour	NULL
granulocytic	NULL
differentiation	NULL
.	NULL

The	NULL
data	NULL
herein	NULL
reported	NULL
also	NULL
suggest	NULL
that	NULL
specific	NULL
regulatory	NULL
programmes	NULL
,	NULL
involving	NULL
distinct	NULL
jun	NULL
144	NULL
F.	NULL
Mollinedo	NULL
and	NULL
others	NULL
proto-oncogenes	NULL
,	NULL
are	NULL
activated	NULL
during	NULL
differentiation	NULL
to	NULL
specific	NULL
myeloid-cell	NULL
lineages	NULL
in	NULL
order	NULL
to	NULL
maintain	NULL
the	NULL
expression	NULL
of	NULL
specific	NULL
cellular	NULL
genes	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Pedro	NULL
Lastres	NULL
for	NULL
expert	NULL
assistance	NULL
on	NULL
the	NULL
flow-cytometry	NULL
experiments	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant	NULL
PM92-0003	NULL
from	NULL
the	NULL
Direccion	NULL
General	NULL
de	NULL
Investigacion	NULL
Cientifica	NULL
y	NULL
Técnica	NULL
(	NULL
to	NULL
F.M	NULL
.	NULL
)	NULL

,	NULL
Grant	NULL
C181/91	NULL
from	NULL
the	NULL
Comunidad	NULL
de	NULL
Madrid	NULL
(	NULL
to	NULL
F.	NULL
M.	NULL
)	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Fundacion	NULL
Ramon	NULL
Areces	NULL
(	NULL
to	NULL
J.R.N	NULL
.	NULL
)	NULL

.	NULL

REFERENCES	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
20	NULL
21	NULL
22	NULL
Collins	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Galto	NULL
,	NULL
R.	NULL
C.	NULL
and	NULL
Gallagher	NULL
,	NULL
R.	NULL
E.	NULL
(	NULL
1977	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
270	NULL
,	NULL
347-349	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Blood	NULL
70	NULL
,	NULL
1233-1244	NULL
Collins	NULL
,	NULL
S.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.	NULL
,	NULL
Gallagher	NULL
,	NULL
R.	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1978	NULL
)	NULL
Proc	NULL
.	NULL

Nati	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
75	NULL
,	NULL
2458-2462	NULL
Breitman	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
Selonick	NULL
,	NULL
S.	NULL
E.	NULL
and	NULL
Collins	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1980	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
T1	NULL
,	NULL
2936-2940	NULL
Rovera	NULL
,	NULL
G.	NULL
,	NULL
Santoli	NULL
,	NULL
D.	NULL
and	NULL
Damsky	NULL
,	NULL
C.	NULL
(	NULL
1979	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
76	NULL
,	NULL
2779-2783	NULL
Boyd	NULL
,	NULL
A.	NULL
W.	NULL
and	NULL
Metcalf	NULL
,	NULL
D.	NULL
(	NULL
1984	NULL
)	NULL
Leukemia	NULL
Res	NULL
.	NULL

8	NULL
,	NULL
27-43	NULL
Mangelsdort	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Koeffler	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Donaldson	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Pike	NULL
,	NULL
J.	NULL
W.	NULL
and	NULL
Haussler	NULL
,	NULL
M.	NULL
R.	NULL
(	NULL
1984	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

98	NULL
,	NULL
391-398	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
and	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
§1	NULL
,	NULL
513-514	NULL
Curran	NULL
,	NULL
T.	NULL
and	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
395-397	NULL
de	NULL
Groot	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Kruyt	NULL
,	NULL
F.	NULL
A.	NULL
E.	NULL
,	NULL
van	NULL
der	NULL
Saag	NULL
,	NULL
P.	NULL
T.	NULL
and	NULL
Kruijer	NULL
,	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
1831-1837	NULL
Bohmann	NULL
,	NULL
D.	NULL
,	NULL
Bos	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
Nishimura	NULL
,	NULL
T.	NULL
,	NULL
Vogt	NULL
,	NULL
P.	NULL
K.	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Science	NULL
238	NULL
,	NULL
1386-1392	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Allegretto	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Okino	NULL
,	NULL
S.	NULL
,	NULL
Hattori	NULL
,	NULL
K.	NULL
,	NULL
Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
332	NULL
,	NULL
166-171	NULL
Halazonetis	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
Georgopoulas	NULL
,	NULL
K.	NULL
,	NULL
Greenberg	NULL
,	NULL
M.	NULL
E.	NULL
and	NULL
Leder	NULL
,	NULL
P.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
917-924	NULL
Rauscher	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
III	NULL
,	NULL
Sambucetti	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
Distel	NULL
,	NULL
R.	NULL
J.	NULL
and	NULL
Spiegelman	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
52	NULL
,	NULL
471-480	NULL
Kouzarides	NULL
,	NULL
T.	NULL
and	NULL
Ziff	NULL
,	NULL
E.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
336	NULL
,	NULL
646-651	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
,	NULL
Ransome	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Lamph	NULL
,	NULL
W.	NULL
W.	NULL
and	NULL
Verma	NULL
,	NULL
1	NULL
.	NULL

M.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
{	NULL
London	NULL
)	NULL
336	NULL
,	NULL
692-695	NULL
Turner	NULL
,	NULL
R.	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
243	NULL
,	NULL
1689-1694	NULL
Schuermann	NULL
,	NULL
M.	NULL
,	NULL
Neuberg	NULL
,	NULL
M.	NULL
,	NULL
Hunter	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Jenuwein	NULL
,	NULL
T.	NULL
,	NULL
Ryseck	NULL
,	NULL
R.-P.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
and	NULL
Miiller	NULL
,	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
§6	NULL
,	NULL
507-516	NULL
Bush	NULL
,	NULL
S.	NULL
J.	NULL
and	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Trends	NULL
Genet	NULL
.	NULL

6	NULL
,	NULL
36-40	NULL
Angel	NULL
,	NULL
P.	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
129-157	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Meek	NULL
,	NULL
J.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
54	NULL
,	NULL
541-552	NULL
Ryder	NULL
,	NULL
K.	NULL
,	NULL
Lanahan	NULL
,	NULL
A.	NULL
,	NULL
Perez-Albuerne	NULL
,	NULL
E.	NULL
and	NULL
Nathans	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
86	NULL
,	NULL
1500-1503	NULL
Received	NULL
23	NULL
November	NULL
1992/16	NULL
March	NULL
1993	NULL
;	NULL
accepted	NULL
22	NULL
March	NULL
1993	NULL
38	NULL
39	NULL
40	NULL
41	NULL
Nakabeppu	NULL
,	NULL
Y.	NULL
,	NULL
Ryder	NULL
,	NULL
K.	NULL
and	NULL
Nathans	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
907-915	NULL
Hirai	NULL
,	NULL
S.-I	NULL
.	NULL

,	NULL
Ryseck	NULL
,	NULL
R.-P.	NULL
,	NULL
Mechta	NULL
,	NULL
F.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
and	NULL
Yaniv	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
.	NULL

J	NULL
.	NULL

8	NULL
,	NULL
1433-1439	NULL
Wilkinson	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Bhatt	NULL
,	NULL
S.	NULL
,	NULL
Ryseck	NULL
,	NULL
R.-P.	NULL
and	NULL
Bravo	NULL
,	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Development	NULL
106	NULL
,	NULL
465-471	NULL
Ryder	NULL
,	NULL
K.	NULL
,	NULL
Lau	NULL
,	NULL
L.	NULL
F.	NULL
and	NULL
Nathans	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
85	NULL
,	NULL
1487-1491	NULL
Mellstrom	NULL
,	NULL
B.	NULL
,	NULL
Achaval	NULL
,	NULL
M.	NULL
,	NULL
Montero	NULL
,	NULL
D.	NULL
,	NULL
Naranjo	NULL
,	NULL
J.	NULL
R.	NULL
and	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
1959-1963	NULL
Moltinedo	NULL
,	NULL
F.	NULL
and	NULL
Naranjo	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

200	NULL
,	NULL
483-486	NULL
Ryseck	NULL
,	NULL
R.-P.	NULL
and	NULL
Bravo	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
533-542	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
979-986	NULL
Mitchell	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Zokas	NULL
,	NULL
L.	NULL
,	NULL
Schreiber	NULL
,	NULL
R.	NULL
D.	NULL
and	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Celt	NULL
40	NULL
,	NULL
209-217	NULL
Brelvi	NULL
,	NULL
Z.	NULL
S.	NULL
and	NULL
Studzinski	NULL
,	NULL
G.	NULL
P.	NULL
(	NULL
1986	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

102	NULL
,	NULL
2234-2243	NULL
Mitchell	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Henning-Chubb	NULL
,	NULL
C.	NULL
,	NULL
Hubermman	NULL
,	NULL
E.	NULL
and	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
45	NULL
,	NULL
497-504	NULL
Calabretta	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

7	NULL
,	NULL
769-774	NULL
Sherman	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Stone	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Datta	NULL
,	NULL
R.	NULL
,	NULL
Bernstein	NULL
,	NULL
S.	NULL
H.	NULL
and	NULL
Kufe	NULL
,	NULL
D.	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biot	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
3320-3323	NULL
Gaynor	NULL
,	NULL
R.	NULL
,	NULL
Simon	NULL
,	NULL
K.	NULL
and	NULL
Koeffler	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Blood	NULL
77	NULL
,	NULL
2618-2623	NULL
Keizer	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
Borst	NULL
,	NULL
J.	NULL
,	NULL
Figdor	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Spits	NULL
,	NULL
H.	NULL
,	NULL
Miedema	NULL
,	NULL
F.	NULL
,	NULL
Terhorst	NULL
,	NULL
C.	NULL
and	NULL
De	NULL
Vries	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1985	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1§	NULL
,	NULL
1142-1148	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
Van	NULL
Beveren	NULL
,	NULL
C.	NULL
,	NULL
Ling	NULL
,	NULL
N.	NULL
and	NULL
Verma	NULL
,	NULL
1	NULL
.	NULL

M.	NULL
(	NULL
1985	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
Biot	NULL
,	NULL
5	NULL
,	NULL
167-172	NULL
Mollinedo	NULL
,	NULL
F.	NULL
,	NULL
Burgaleta	NULL
,	NULL
C.	NULL
,	NULL
Velasco	NULL
,	NULL
G.	NULL
,	NULL
Arroyo	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Acevedo	NULL
,	NULL
A.	NULL
and	NULL
Barasoain	NULL
,	NULL
1	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
323-330	NULL
Chirgwin	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Przybyla	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
MacDonald	NULL
,	NULL
R.	NULL
J.	NULL
and	NULL
Rutter	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Biochemistry	NULL
18	NULL
,	NULL
5294-5299	NULL
Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
Feinberg	NULL
,	NULL
A.	NULL
P.	NULL
and	NULL
Vogelstein	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

182	NULL
,	NULL
6-13	NULL
Auwerx	NULL
,	NULL
J.	NULL
,	NULL
Staels	NULL
,	NULL
B.	NULL
and	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18	NULL
,	NULL
221-228	NULL
Ryseck	NULL
,	NULL
R.-P.	NULL
,	NULL
Hirai	NULL
,	NULL
S.	NULL
I.	NULL
,	NULL
Yaniv	NULL
,	NULL
M.	NULL
and	NULL
Bravo	NULL
,	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
334	NULL
,	NULL
535-537	NULL
Mollinedo	NULL
,	NULL
F.	NULL
,	NULL
Vaquerizo	NULL
,	NULL
M.	NULL
J.	NULL
and	NULL
Naranjo	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

278	NULL
,	NULL
477-479	NULL
Schreiber	NULL
,	NULL
E.	NULL
,	NULL
Matthias	NULL
,	NULL
P.	NULL
,	NULL
Miller	NULL
,	NULL
M.	NULL
M.	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
6419	NULL
Bradford	NULL
,	NULL
M.	NULL
M.	NULL
(	NULL
1976	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

72	NULL
,	NULL
248-254	NULL
Hattori	NULL
,	NULL
M.	NULL
,	NULL
Abraham	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
Northemann	NULL
,	NULL
W.	NULL
and	NULL
Fey	NULL
,	NULL
G.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
87	NULL
,	NULL
2364-2368	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Rahmsdor	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Jonat	NULL
,	NULL
C.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
729-739	NULL
Milter	NULL
,	NULL
R.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
Burckhardt	NULL
,	NULL
J.	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1984	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
312	NULL
,	NULL
716-720	NULL
Montminy	NULL
,	NULL
M.	NULL
R.	NULL
and	NULL
Bilezikjian	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
328	NULL
,	NULL
175-178	NULL
Jones	NULL
,	NULL
N.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
61	NULL
,	NULL
9-11	NULL
Hai	NULL
,	NULL
T.	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
88	NULL
,	NULL
3720-3724	NULL
Nakamura	NULL
,	NULL
T.	NULL
,	NULL
Datta	NULL
,	NULL
R.	NULL
,	NULL
Sherman	NULL
,	NULL
M.	NULL
L.	NULL
and	NULL
Kufe	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
22011-22015	NULL
Datta	NULL
,	NULL
R.	NULL
,	NULL
Nakamura	NULL
,	NULL
T.	NULL
,	NULL
Sherman	NULL
,	NULL
M.	NULL
L.	NULL
and	NULL
Kufe	NULL
,	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Blood	NULL
78	NULL
,	NULL
83-88	NULL
Naranjo	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Mellstrom	NULL
,	NULL
8.	NULL
,	NULL
Auwerx	NULL
,	NULL
J.	NULL
,	NULL
Mollinedo	NULL
,	NULL
F.	NULL
and	NULL
Sassone-Corsi	NULL
,	NULL
P.	NULL
(	NULL
1990	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18	NULL
,	NULL
3605-3610	NULL

